<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id><journal-id journal-id-type="pmc">plosbiol</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Biology</journal-title></journal-title-group><issn pub-type="ppub">1544-9173</issn><issn pub-type="epub">1545-7885</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PBIOLOGY-D-11-02459</article-id><article-id pub-id-type="doi">10.1371/journal.pbio.1001194</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Neuroscience</subject>
            <subj-group>
              <subject>Neurochemistry</subject>
              <subj-group>
                <subject>Neuromodulation</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Animal cognition</subject>
              <subject>Neuroimaging</subject>
              <subject>Neurotransmitters</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Anatomy and physiology</subject>
            <subj-group>
              <subject>Neurological system</subject>
              <subj-group>
                <subject>Central nervous system</subject>
                <subject>Motor systems</subject>
                <subject>Nervous system physiology</subject>
                <subject>Synapses</subject>
              </subj-group>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Mental health</subject>
            <subj-group>
              <subject>Psychiatry</subject>
              <subj-group>
                <subject>Neuropsychiatric disorders</subject>
                <subject>Substance abuse</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Mental Health</subject>
          <subject>Physiology</subject>
          <subject>Neuroscience</subject>
        </subj-group>
      </article-categories><title-group><article-title>Elimination of the Vesicular Acetylcholine Transporter in the Striatum Reveals Regulation of Behaviour by Cholinergic-Glutamatergic Co-Transmission</article-title><alt-title alt-title-type="running-head">Acetylcholine and Striatal-Dependent Behaviours</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Guzman</surname>
            <given-names>Monica S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>De Jaeger</surname>
            <given-names>Xavier</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Raulic</surname>
            <given-names>Sanda</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Souza</surname>
            <given-names>Ivana A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Li</surname>
            <given-names>Alex X.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Schmid</surname>
            <given-names>Susanne</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Menon</surname>
            <given-names>Ravi S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gainetdinov</surname>
            <given-names>Raul R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Caron</surname>
            <given-names>Marc G.</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Bartha</surname>
            <given-names>Robert</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Prado</surname>
            <given-names>Vania F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Prado</surname>
            <given-names>Marco A. M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Molecular Brain Research Group, Robarts Research Institute, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, Ontario, Canada</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Department of Physiology and Pharmacology, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, Ontario, Canada</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>Department of Anatomy &amp; Cell Biology, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, Ontario, Canada</addr-line>       </aff><aff id="aff4"><label>4</label><addr-line>Program in Molecular Pharmacology, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil</addr-line>       </aff><aff id="aff5"><label>5</label><addr-line>Imaging Research Group, Robarts Research Institute, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, Ontario, Canada</addr-line>       </aff><aff id="aff6"><label>6</label><addr-line>Department of Medical Biophysics, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, Ontario, Canada</addr-line>       </aff><aff id="aff7"><label>7</label><addr-line>Department of Neuroscience and Brain Technologies, Italian Institute of Technology, Genova, Italy</addr-line>       </aff><aff id="aff8"><label>8</label><addr-line>Department of Cell Biology, Duke University Medical Center, Durham, North Carolina, United States of America</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Nestler</surname>
            <given-names>Eric</given-names>
          </name>
          <role>Academic Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">Mount Sinai School of Medicine, United States of America</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">mprado@robarts.ca</email> (MAMP); <email xlink:type="simple">vprado@robarts.ca</email> (VFP)</corresp>
        <fn fn-type="con">
          <p>The author(s) have made the following declarations about their contributions: Conceived and designed the experiments: RB VFP MAMP MSG XDeJ SS RRG MGC. Performed the experiments: MSG XDeJ SR IAS AXL SS. Analyzed the data: MSG XDeJ IAS AXL SS RSM RB VFP MAMP. Contributed reagents/materials/analysis tools: MGC. Wrote the paper: VFP MAMP.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <month>11</month>
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>8</day>
        <month>11</month>
        <year>2011</year>
      </pub-date><volume>9</volume><issue>11</issue><elocation-id>e1001194</elocation-id><history>
        <date date-type="received">
          <day>15</day>
          <month>6</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>9</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Guzman et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract abstract-type="toc">
        <p>A novel mouse model that eliminates cholinergic neurotransmission in the striatum while leaving glutamate release intact reveals differential effects on cocaine-induced behavior and dopaminergic responses.</p>
      </abstract><abstract>
        <p>Cholinergic neurons in the striatum are thought to play major regulatory functions in motor behaviour and reward. These neurons express two vesicular transporters that can load either acetylcholine or glutamate into synaptic vesicles. Consequently cholinergic neurons can release both neurotransmitters, making it difficult to discern their individual contributions for the regulation of striatal functions. Here we have dissected the specific roles of acetylcholine release for striatal-dependent behaviour in mice by selective elimination of the vesicular acetylcholine transporter (VAChT) from striatal cholinergic neurons. Analysis of several behavioural parameters indicates that elimination of VAChT had only marginal consequences in striatum-related tasks and did not affect spontaneous locomotion, cocaine-induced hyperactivity, or its reward properties. However, dopaminergic sensitivity of medium spiny neurons (MSN) and the behavioural outputs in response to direct dopaminergic agonists were enhanced, likely due to increased expression/function of dopamine receptors in the striatum. These observations indicate that previous functions attributed to striatal cholinergic neurons in spontaneous locomotor activity and in the rewarding responses to cocaine are mediated by glutamate and not by acetylcholine release. Our experiments demonstrate how one population of neurons can use two distinct neurotransmitters to differentially regulate a given circuitry. The data also raise the possibility of using VAChT as a target to boost dopaminergic function and decrease high striatal cholinergic activity, common neurochemical alterations in individuals affected with Parkinson's disease.</p>
      </abstract><abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>The neurotransmitters dopamine and acetylcholine play opposite roles in the striatum (a brain region involved in motor control and reward-related behaviour), and their balance is thought to be critical for striatal function. Acetylcholine in the striatum has been linked to a number of functions, including control of locomotor activity and response to drugs of abuse. However, striatal cholinergic interneurons can also release glutamate (in addition to acetylcholine) and it is presently unclear how these two neurotransmitters regulate striatal-dependent behaviour. Previous work has attempted to resolve this issue by ablating cholinergic neurons in the striatum, but this causes loss of both cholinergic and glutamatergic neurotransmission. In this study, we created a novel genetic mouse model which allowed us to selectively interfere with secretion of acetylcholine in the striatum, while leaving total striatal glutamate release intact. In these mice, we observed minimally altered behavioural responses to cocaine, suggesting that striatal glutamate, rather than acetylcholine, is critical for cocaine-induced behavioural manifestations. Furthermore, elimination of striatal acetylcholine release affects how striatal output neurons respond to dopamine, by up-regulating dopaminergic receptors and changing behavioural responses to dopaminergic agonists. Our experiments highlight a previously unappreciated physiological role of cholinergic-glutamatergic co-transmission and demonstrate how a population of neurons can use two distinct neurotransmitters to differentially regulate behaviour.</p>
      </abstract><funding-group><funding-statement>This work was supported by the Canadian Institutes of Health Research (CIHR), Canadian Foundation for Innovation (CFI), and the Ontario Research Fund (ORF). MGC received support from the NIH. XDeJ and IAS received PhD fellowships from CAPES (Brazil). IAS also received support from the Emerging Leaders of America Program (ELAP) from the Department of Foreign Affairs and International Trade (Canada). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="16"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>The striatum is the major input gateway to the basal ganglia. Striatal activity plays important roles in controlling motor functions and goal-directed and reward-related behaviours <xref ref-type="bibr" rid="pbio.1001194-Aosaki1">[1]</xref>–<xref ref-type="bibr" rid="pbio.1001194-Calabresi1">[4]</xref>. The striatum is the brain region mostly affected in motor diseases, such as Parkinson's disease (PD), Huntington's disease, and dystonia <xref ref-type="bibr" rid="pbio.1001194-Pisani1">[5]</xref>. Medium spiny GABAergic neurons (MSN), activated by corticostriatal glutamatergic inputs, are the major output neurons for the striatum; these neurons are regulated extensively by the classical neurotransmitters dopamine and acetylcholine (ACh) <xref ref-type="bibr" rid="pbio.1001194-Aosaki1">[1]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Lovinger1">[2]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Calabresi1">[4]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Shen1">[6]</xref>. These two neurotransmitters have reciprocal relationships, regulating each other's release at different levels, and they generally have opposing actions in the direct and indirect striatal pathways <xref ref-type="bibr" rid="pbio.1001194-Aosaki1">[1]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Pisani1">[5]</xref>,<xref ref-type="bibr" rid="pbio.1001194-MacKenzie1">[7]</xref>–<xref ref-type="bibr" rid="pbio.1001194-DeBoer2">[9]</xref>. Regulation of MSNs by dopamine has received considerable attention, largely due to the well-known effects of reduced dopamine levels leading to motor symptoms in PD <xref ref-type="bibr" rid="pbio.1001194-RodriguezOroz1">[10]</xref> and the role of dopamine in the effect of drugs of abuse <xref ref-type="bibr" rid="pbio.1001194-Torres1">[11]</xref>.</p>
      <p>In contrast to the widely known effects of dopamine in the striatum, we know considerably less about how ACh shapes striatal function. Cholinergic neurons form a small population of aspiny and large striatal interneurons that provide the sole source of cholinergic innervation to MSNs <xref ref-type="bibr" rid="pbio.1001194-Bennett1">[12]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Wilson1">[13]</xref>. These neurons fire constantly and therefore ensure relatively high levels of extracellular ACh. To maintain high levels of transmitter release, cholinergic neurons transport ACh synthesized in the cytoplasm into synaptic vesicles, a process which requires the activity of the vesicular acetylcholine transporter (SLC18A3, VAChT <xref ref-type="bibr" rid="pbio.1001194-Parsons1">[14]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Ribeiro1">[15]</xref>), the last cholinergic-specific step for ACh-mediated neurotransmission <xref ref-type="bibr" rid="pbio.1001194-deCastro1">[16]</xref>. A variety of muscarinic receptors <xref ref-type="bibr" rid="pbio.1001194-Wess1">[17]</xref>, as well as nicotinic subtypes of receptors <xref ref-type="bibr" rid="pbio.1001194-Zhou1">[18]</xref>–<xref ref-type="bibr" rid="pbio.1001194-Drenan2">[21]</xref>, involved in controlling striatal function add complexity to unravelling the role of endogenous ACh in the striatum. To make matters more difficult, several central cholinergic neurons express both VAChT and distinct vesicular glutamate transporters (VGLUTs) and thus are able to store and release both ACh and glutamate <xref ref-type="bibr" rid="pbio.1001194-Ren1">[22]</xref>. Striatal cholinergic neurons express VGLUT3 <xref ref-type="bibr" rid="pbio.1001194-Fremeau1">[23]</xref>–<xref ref-type="bibr" rid="pbio.1001194-Seal1">[26]</xref> and simultaneously release glutamate and ACh <xref ref-type="bibr" rid="pbio.1001194-Higley1">[27]</xref>. It is unknown, however, if cholinergic neurons can use both neurotransmitters to regulate striatal function.</p>
      <p>Elimination of cholinergic neurons in the striatum, using ablation strategies, indicated that these neurons have a role in regulating spontaneous and cocaine-induced locomotor activity, as well as its rewarding properties <xref ref-type="bibr" rid="pbio.1001194-Hikida1">[28]</xref>–<xref ref-type="bibr" rid="pbio.1001194-Kitabatake1">[31]</xref>. These neurons have the capacity to release both ACh and glutamate; therefore, non-selective manipulations of striatal cholinergic neurons can affect both VAChT and VGLUT-mediated neurotransmission. Interestingly, mice null for VGLUT3 phenocopy many of the behavioural alterations found in mice that had their accumbens cholinergic neurons ablated <xref ref-type="bibr" rid="pbio.1001194-Gras1">[25]</xref>. However, because VGLUT3-null mice also presented a 40% decrease on acetylcholine release, it is difficult to discern the individual effects of these two neurotransmitters. Therefore, the specific roles of ACh for striatal function have not yet been addressed.</p>
      <p>To investigate the possibility that cholinergic neurons can use these two distinct neurotransmitters differentially to regulate striatal circuitry, we generated a novel mouse line in which we selectively eliminated ACh release by deleting the VAChT gene in the striatum. Our results reveal specific roles for ACh release in regulating dopamine receptor-mediated locomotor responses, but suggest that some of the previous functions attributed to these neurons are related to their ability to release glutamate.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>D2-Cre Mice Express Cre in Striatal Cholinergic Neurons</title>
        <p>To address specific roles of ACh release in striatal function we generated a VAChT floxed mouse line (VAChT<sup>flox/flox</sup>, <xref ref-type="bibr" rid="pbio.1001194-MartinsSilva1">[32]</xref>), as constitutive VAChT knockout mice do not survive birth due to impaired breathing <xref ref-type="bibr" rid="pbio.1001194-deCastro1">[16]</xref>. The addition of lox P sites did not change VAChT expression at the mRNA and protein levels when compared to wild-type control mice. VAChT<sup>flox/flox</sup> mice had normal levels of VAChT and other pre-synaptic cholinergic markers. In addition locomotor activity, grip-strength, and fatigue were identical in VAChT<sup>flox/flox</sup> mice and wild-type mice <xref ref-type="bibr" rid="pbio.1001194-MartinsSilva1">[32]</xref>.</p>
        <p>In order to selectively eliminate VAChT in the striatum, we used the D2-Cre bacterial artificial chromosome (BAC) transgenic mouse line generated by GENSAT <xref ref-type="bibr" rid="pbio.1001194-Gong1">[33]</xref>, which expresses the enzyme Cre recombinase under the control of regulatory elements of the D2 dopamine receptor (D2R). Details related to this mouse line, including control experiments demonstrating that the expression of Cre has no effects on the parameters studied here, are presented in Experimental Procedures and <xref ref-type="supplementary-material" rid="pbio.1001194.s006">Figure S6</xref>. To test whether Cre was expressed in striatal cholinergic neurons, we crossed D2-Cre mice to <italic>Rosa26</italic> reporter mice (<italic>Rosa26</italic>-YFP mice), in which the <italic>Rosa26</italic> locus expresses YFP once Cre-mediated recombination has occurred (<xref ref-type="fig" rid="pbio-1001194-g001">Figure 1a</xref>). We found that in D2-Cre;Rosa26-YFP mice almost 100% of striatal cholinergic neurons identified with an antibody against CHT1 also showed Cre-recombination (YFP staining 98% co-localization, <xref ref-type="supplementary-material" rid="pbio.1001194.s007">Table S1</xref>). We did not detect co-localization of YFP in cholinergic neurons in the penduculopontine nucleus or in motoneurons in the brainstem (<xref ref-type="supplementary-material" rid="pbio.1001194.s001">Figure S1</xref> and <xref ref-type="supplementary-material" rid="pbio.1001194.s007">Table S1</xref>). Partial localization of YFP in cholinergic neurons was detected in the basal forebrain, albeit to a much lower extent than in the striatum (approx. 50%, <xref ref-type="fig" rid="pbio-1001194-g001">Figure 1b</xref> and <xref ref-type="supplementary-material" rid="pbio.1001194.s007">Table S1</xref>). We therefore intercrossed D2-Cre mice to VAChT<sup>flox/flox</sup> mice to generate mice with selective elimination of VAChT in the striatum (VAChT<sup>D2-Cre-flox/flox</sup>) or control mice (VAChT<sup>flox/flox</sup>). Genotyping for these lines is shown in <xref ref-type="supplementary-material" rid="pbio.1001194.s002">Figure S2</xref>. VAChT<sup>D2-Cre-flox/flox</sup> mice were born in the expected Mendellian ratio and did not present overt phenotypes. We found no gross morphological alterations in the striatum or other brain sections stained with hematoxylin/eosin in VAChT<sup>D2-Cre-flox/flox</sup> mice compared to control mice (unpublished data).</p>
        <fig id="pbio-1001194-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>D2-Cre drives the expression of Cre in striatal cholinergic neurons.</title>
            <p>(a) Expression pattern of Cre detected by staining for YFP in the brain of D2-Cre;Rosa26-YFP mice. (b) Sections from different regions of the central nervous system were immunostained for CHT1 (Red) and YFP (Green) in D2-Cre;Rosa26-YFP mice. Arrows show localization of Cre expression (YFP) in cholinergic neurons (CHT1 staining). Arrowheads show cholinergic neurons that do not express Cre. For additional brain regions, see <xref ref-type="supplementary-material" rid="pbio.1001194.s001">Figure S1</xref> and <xref ref-type="supplementary-material" rid="pbio.1001194.s007">Table S1</xref>.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g001" xlink:type="simple"/>
        </fig>
        <p>To assess the degree of Cre-mediated recombination we evaluated the expression of VAChT in the striatum of VAChT<sup>D2-Cre-flox/flox</sup>. As expected, based on the observations with the D2-Cre;Rosa26-YFP mice, both mRNA and protein levels for VAChT were almost abolished in the striatum of VAChT<sup>D2-Cre-flox/flox</sup> (<xref ref-type="fig" rid="pbio-1001194-g002">Figure 2a,d,g</xref>). In contrast, choline acetyltransferase (ChAT) and the high-affinity choline transporter (CHT1) protein levels were not altered (<xref ref-type="fig" rid="pbio-1001194-g002">Figure 2e and f</xref>). There was no difference in VAChT protein expression levels in the hippocampus of VAChT<sup>D2-Cre-flox/flox</sup> mice when compared to controls (<xref ref-type="fig" rid="pbio-1001194-g002">Figure 2h and i</xref>). Accordingly, release of [<sup>3</sup>H]-ACh was abolished in striatal slices from VAChT<sup>D2-Cre-flox/flox</sup> mice depolarized with high KCl, whereas it was identical to controls in hippocampal slices (<xref ref-type="fig" rid="pbio-1001194-g003">Figure 3a and b</xref>).</p>
        <fig id="pbio-1001194-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Expression of VAChT in the striatum of VAChT<sup>D2-Cre-flox/flox</sup> mice.</title>
            <p>(a)VAChT mRNA expression, (b) ChAT mRNA expression, (c) CHT1 mRNA expression, (d) VAChT protein expression, (e) ChaT protein expression, (f) CHT1 protein expression, (g) representative immunoblot of control and VAChT<sup>D2-Cre-flox/flox</sup> striatal tissue, (h) VAChT protein expression in the hippocampus, and (i) representative immunoblot of protein expression in the hippocampus. ** <italic>p</italic>&lt;0.01 *** <italic>p</italic>&lt;0.001. mRNA expression levels were quantified by qPCR using actin to normalize the data, and figures represent <italic>N</italic> = 5 mice. Protein levels were quantified using synaptophysin as a loading control. <italic>N</italic> = 5 mice. See <xref ref-type="supplementary-material" rid="pbio.1001194.s002">Figure S2</xref> for VAChT levels in the spinal cord.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g002" xlink:type="simple"/>
        </fig>
        <fig id="pbio-1001194-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Release of acetylcholine and glutamate from VAChT<sup>D2-Cre-flox/flox</sup> mice.</title>
            <p>(a) Release of [<sup>3</sup>H]ACh from striatal slices in response to depolarization with KCl (33 mM). Basal release was subtracted from stimulated release to obtain only evoked release. *** <italic>p</italic>&lt;0.001. (b) Release of [<sup>3</sup>H]ACh from hippocampal slices performed as in (a). (c) Release of glutamate from striatal isolated nerve terminals and (d) expression of VGLUT 3 in the striatum. <italic>N</italic> = 5.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g003" xlink:type="simple"/>
        </fig>
        <p>Acetylcholine can modulate glutamate release via pre-synaptic nicotinic receptors in projection glutamatergic nerve-terminals <xref ref-type="bibr" rid="pbio.1001194-Campos1">[34]</xref>. In addition, striatal cholinergic neurons can also release glutamate <xref ref-type="bibr" rid="pbio.1001194-Higley1">[27]</xref>. Therefore, we examined if there was any effect of VAChT elimination on glutamate release. Isolated nerve terminals were obtained from striatal tissue of VAChT<sup>D2-Cre-flox/flox</sup> and control mice and glutamate release was stimulated by KCl. We did not detect changes in glutamate release from isolated nerve terminals in VAChT-deficient mice compared to controls (<xref ref-type="fig" rid="pbio-1001194-g003">Figure 3c</xref>). It should be noted, however, that this method does not separate terminals containing VGLUT3 from nerve terminals containing other VGLUTs, and therefore only reflects global changes in glutamate release. Moreover, VGLUT3 mRNA expression by qPCR did not differ in VAChT<sup>D2-Cre-flox/flox</sup> mice compared to control mice (<xref ref-type="fig" rid="pbio-1001194-g003">Figure 3d</xref>). These results suggest that overall glutamate release is not grossly altered in these mice.</p>
      </sec>
      <sec id="s2b">
        <title>VAChT<sup>D2-Cre-flox/flox</sup> Mice Do Not Show Motor Deficits</title>
        <p>Because we detected the presence of Cre-mediated recombination in motoneurons in the spinal cord (<xref ref-type="supplementary-material" rid="pbio.1001194.s001">Figure S1</xref>), which could affect the behavioural performance in VAChT<sup>D2-Cre-flox/flox</sup> mice, we examined the cholinergic system in the spinal cord of VAChT<sup>D2-Cre-flox/flox</sup> mice. We did not find alterations in mRNA levels for VAChT in the spinal cord of VAChT<sup>D2-Cre-flox/flox</sup> mice (<xref ref-type="supplementary-material" rid="pbio.1001194.s003">Figure S3</xref>). However, we detected an increase in ChAT mRNA and protein levels in the spinal cord. Surprisingly, there was also about a 50% decrease in VAChT protein levels. Previous experiments showed that up to a 50% decrease in the expression of VAChT in the spinal cord is well tolerated in mice and does not alter motor function <xref ref-type="bibr" rid="pbio.1001194-deCastro2">[35]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>. In agreement with these previous results, VAChT<sup>D2-Cre-flox/flox</sup> mice showed no difference in grip-force strength (<xref ref-type="supplementary-material" rid="pbio.1001194.s004">Figure S4a</xref>, <italic>t</italic><sub>(47)</sub> = 1.702, <italic>p</italic> = 0.095) or fatigue (detected by the Wire-hang task, <xref ref-type="supplementary-material" rid="pbio.1001194.s004">Figure S4b</xref>, Mann-Whitney, T<sub>(13)</sub> = 49, <italic>p</italic> = 0.710). Interestingly, we also found that relative to controls, VAChT<sup>D2-Cre-flox/flox</sup> mice showed no deficit in motor performance or motor learning assessed using the rotarod test (<xref ref-type="supplementary-material" rid="pbio.1001194.s004">Figure S4c</xref>, Repeated Measures ANOVA reveal no difference between the two genotypes with respect to time to fall, <italic>F</italic><sub>(1,261)</sub> = 0.0000409, <italic>p</italic> = 0.995; both sets of mice improved their performance, <italic>F</italic><sub>(9,261)</sub> = 41.614, <italic>p</italic>&lt;0.001; and there was no interaction between genotype and session, <italic>F</italic><sub>(9,261)</sub> = 1.333, <italic>p</italic> = 0.220). These results show that despite a decrease in the levels of VAChT in the spinal cord there were no detectable changes in motor function. The rotarod experiments also suggest that VAChT<sup>D2-Cre-flox/flox</sup> mice are physically fit and that motor learning does not appear to depend on striatal cholinergic activity.</p>
      </sec>
      <sec id="s2c">
        <title>VAChT<sup>D2-Cre-flox/flox</sup> Mice Do Not Show Broad Cognitive Deficits</title>
        <p>Next, as a further control experiment, we determined if the elimination of ACh release in the striatum could interfere with cognitive performance that is believed to be generally independent of striatal function. We used object recognition memory, a task that is thought to be dependent on the hippocampus <xref ref-type="bibr" rid="pbio.1001194-Clarke1">[37]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Rossato1">[38]</xref> and perirhinal cortex <xref ref-type="bibr" rid="pbio.1001194-Winters1">[39]</xref>, and has been previously shown to be sensitive to global decreases in VAChT levels <xref ref-type="bibr" rid="pbio.1001194-deCastro2">[35]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Capettini1">[40]</xref>. In this test VAChT<sup>D2-Cre-flox/flox</sup> mice performed identically to controls, suggesting that important cognitive functions are preserved in this new mouse line (<xref ref-type="supplementary-material" rid="pbio.1001194.s004">Figure S4d</xref>, two-way ANOVA revealed no effect of genotype, <italic>F</italic><sub>(1,16)</sub> = 0.651, <italic>p</italic> = 0.431, a significant effect for object, <italic>F</italic><sub>(1,16)</sub> = 21.559, <italic>p</italic>&lt;0.001 and no Object × Genotype interaction, <italic>F</italic><sub>(1,16)</sub> = 0.0185, <italic>p</italic> = 0.893).</p>
        <p>Previous experiments have shown that the density of cholinergic neurons in the accumbens, as well as expression of ChAT, is decreased in the post-mortem brain of schizophrenic individuals <xref ref-type="bibr" rid="pbio.1001194-Holt1">[41]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Holt2">[42]</xref>. Moreover, partial ablation of cholinergic striatal neurons caused alterations in sensorimotor gating <xref ref-type="bibr" rid="pbio.1001194-Laplante1">[43]</xref>. Therefore, we used habituation to acoustic startle and pre-pulse inhibition to assess sensorimotor gating, but found no effects of elimination of striatal VAChT on these parameters (<xref ref-type="supplementary-material" rid="pbio.1001194.s005">Figure S5</xref>). These results show that decreased striatal ACh release does not cause sensorimotor gating dysfunctions in these animals and likely in schizophrenia as well.</p>
      </sec>
      <sec id="s2d">
        <title>VAChT<sup>D2-Cre-flox/flox</sup> Mice Have Normal Spontaneous Locomotion</title>
        <p>There are controversial views regarding the role of striatal cholinergic neurons in locomotion. Previous experiments in which cholinergic neurons in the nucleus accumbens were ablated indicated that loss of these neurons caused hyperlocomotion and increased sensitivity to the locomotor effects of cocaine <xref ref-type="bibr" rid="pbio.1001194-Hikida2">[29]</xref>–<xref ref-type="bibr" rid="pbio.1001194-Kitabatake1">[31]</xref>. However, more recent experiments using an optogenetics approach failed to detect an increased locomotor activity in mice in which striatal cholinergic neurons were acutely silenced <xref ref-type="bibr" rid="pbio.1001194-Witten1">[44]</xref>. In agreement with the latter, we found no differences in locomotor activity when we compared VAChT<sup>D2-Cre-flox/flox</sup> mice to controls (<xref ref-type="fig" rid="pbio-1001194-g004">Figure 4a</xref>). The dynamics of total horizontal activity (<xref ref-type="fig" rid="pbio-1001194-g004">Figure 4a and 4b</xref>, <italic>t</italic><sub>(48)</sub> = 0.1464; <italic>p</italic> = 0.884) or counts of vertical activity (unpublished data, <italic>t</italic><sub>(24)</sub> = 1.027; <italic>p</italic> = 0.315) were essentially identical in the two strains. Importantly, in control experiments D2-Cre mice did not differ in locomotor activity from respective wild type mice (<xref ref-type="supplementary-material" rid="pbio.1001194.s006">Figure S6</xref>).</p>
        <fig id="pbio-1001194-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Locomotor activity of VAChT<sup>D2-Cre-flox/flox</sup> mice.</title>
            <p>(a) Horizontal locomotor activity in an open-field for VAChT<sup>D2-Cre-flox/flox</sup> (<italic>N</italic> = 24) and control mice (<italic>N</italic> = 27). (b) Cumulative 2 h locomotion VAChT<sup>D2-Cre-flox/flox</sup> (<italic>N</italic> = 24) and control mice (<italic>N</italic> = 27) (c) dark cycle activity of VAChT<sup>D2-Cre-flox/flox</sup> (<italic>N</italic> = 16) and control mice (<italic>N</italic> = 15). (d) Total locomotion activity during the first initial hours of the dark-cycle. (e) Habituation in the open-field measured as cumulative 2 h locomotion for VAChT<sup>D2-Cre-flox/flox</sup> and control mice in 3 consecutive days. ** <italic>p</italic>&lt;0.01, *** <italic>p</italic>&lt;0.001 compared to the first day. VAChT<sup>D2-Cre-flox/flox</sup> <italic>N</italic> = 10; control mice <italic>N</italic> = 21.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g004" xlink:type="simple"/>
        </fig>
        <p>It has been shown that VGLUT3-null mice present hyperactivity, which was attributed to decreased ACh release from striatal cholinergic neurons due to decreased filling of synaptic vesicles with ACh <xref ref-type="bibr" rid="pbio.1001194-Gras1">[25]</xref>. Because these experiments with VGLUT3-null mice were performed in the initial hours of the dark cycle, we reproduced these conditions with a new cohort of our mice. The VAChT<sup>D2-Cre-flox/flox</sup> mice were no more active than their control counterparts during the first hours of the dark cycle (<xref ref-type="fig" rid="pbio-1001194-g004">Figure 4c and d</xref>, repeated measures ANOVA shows no main effect of genotype, <italic>F</italic><sub>(1,1593)</sub> = 0.321, <italic>p</italic> = 0.576, significant effect of time, <italic>F</italic><sub>(59,1593)</sub> = 14.411, <italic>p</italic>&lt;0.001 and no interaction Genotype × Time, <italic>F</italic><sub>(59,1593)</sub> = 0.947, <italic>p</italic> = 0.591; total activity was not different, Mann-Whitney, T<sub>(29)</sub> = 213, <italic>p</italic> = 0.431). Finally, we also tested inter-session habituation by investigating locomotor activity in 3 consecutive days in the open-field (<xref ref-type="fig" rid="pbio-1001194-g004">Figure 4e</xref>). We observed that both genotypes habituated similarly to the open-field. Repeated measures ANOVA confirmed that the general activity was the same for both genotypes (genotype factor, <italic>F</italic><sub>(1,58)</sub> = 0.932, <italic>p</italic> = 0.342). The activity decreased over the day (day factor, <italic>F</italic><sub>(2,58)</sub> = 10.244, <italic>p</italic>&lt;0.001) and both genotypes habituated to the environment at comparable rates (interaction between genotype and day, <italic>F</italic><sub>(2,58)</sub> = 1.506, <italic>p</italic> = 0.230). Evidently, deletion of VAChT in the striatum does not affect general spontaneous activity or compromise the capacity to habituate to a new environment.</p>
      </sec>
      <sec id="s2e">
        <title>Responses of VAChT<sup>D2-Cre-flox/flox</sup> Mice to Cocaine</title>
        <p>Previous experiments in mice in which cholinergic interneurons were ablated suggested that decreased ACh levels increase sensitivity of mice to the locomotor effects of cocaine <xref ref-type="bibr" rid="pbio.1001194-Hikida2">[29]</xref>–<xref ref-type="bibr" rid="pbio.1001194-Kitabatake1">[31]</xref>. However, these experiments did not separate the effects of VAChT and VGLUT3-mediated transmission. Interestingly, VGLUT3-null mice are also more sensitive to the locomotor effects of cocaine, a result that was attributed at least in part to a decrease in striatal ACh release <xref ref-type="bibr" rid="pbio.1001194-Gras1">[25]</xref>. Due to the surprising observations of normal locomotor activity in VAChT-deficient mice, we investigated the specific effects of the elimination of VAChT-mediated neurotransmission on the actions of cocaine. Administration of 5, 20, or 40 mg/kg of cocaine increased locomotor activity in VAChT<sup>flox/flox</sup> mice and VAChT<sup>D2-Cre-flox/flox</sup> mice (<xref ref-type="fig" rid="pbio-1001194-g005">Figure 5c</xref>, two-factor ANOVAs show a significant effect of genotype, <italic>F</italic><sub>(1,51)</sub> = 6.531, <italic>p</italic> = 0.014, significant effect of treatment, <italic>F</italic><sub>(3,51)</sub> = 15.611, <italic>p</italic>&lt;0.001, and no Genotype × Treatment interaction, <italic>F</italic><sub>(3,51)</sub> = 0.983, <italic>p</italic> = 0.381). There was no difference between the two genotypes in their ability to increase activity in response to cocaine-injected i.p. at 5 mg/kg dose (<xref ref-type="fig" rid="pbio-1001194-g005">Figure 5a,</xref> 5 mg/kg, repeated measures ANOVAs show no effect of genotype, <italic>F</italic><sub>(1,322)</sub> = 0.201, <italic>p</italic> = 0.661, significant effect of time, <italic>F</italic><sub>(23,322)</sub> = 12.820, <italic>p</italic>&lt;0.001, and no Time × Genotype interaction, <italic>F</italic><sub>(23,322)</sub> = 1.373, <italic>p</italic> = 0.121). Paradoxically, at 20 mg/kg VAChT<sup>D2-Cre-flox/flox</sup> mice showed a smaller effect of cocaine in locomotor activity than controls (<xref ref-type="fig" rid="pbio-1001194-g005">Figure 5b</xref>, 20 mg/kg, repeated measures ANOVA shows significant effect of genotype, <italic>F</italic><sub>(1,480)</sub> =  11.345, <italic>p</italic>&lt;0.001, significant effect of time, <italic>F</italic><sub>(23,480)</sub> = 9.464, <italic>p</italic>&lt;0.001, and no Time × Genotype interaction, <italic>F</italic><sub>(23,480)</sub> = 0.945, <italic>p</italic> = 0.537). Analysis of total activity counts showed a clear effect of genotype (<xref ref-type="fig" rid="pbio-1001194-g005">Figure 5c</xref>, Mann-Whitney, T<sub>(23)</sub> = 166.000, <italic>p</italic>&lt;0.05). At 40 mg/kg both genotypes showed similar responses (<xref ref-type="fig" rid="pbio-1001194-g005">Figure 5c,</xref> <italic>t</italic><sub>(14)</sub> = 0.980, <italic>p</italic> = 0.344), suggesting that lack of striatal VAChT altered the response to 20 mg/kg of cocaine, but overall did not cause increased sensitivity to locomotor effects of cocaine.</p>
        <fig id="pbio-1001194-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>Cocaine-mediated locomotor activity in VAChT<sup>D2-Cre-flox/flox</sup> mice.</title>
            <p>(a) Mice were injected with 5 mg/kg of cocaine after 20 min in the open-field and horizontal locomotor activity was measured. (b) Locomotor activity before and after injection of 20 mg/kg of cocaine. As with 5 mg/kg the mice were injected with cocaine after 20 min in the open-field. (c) Total locomotion during the 20 min following cocaine injection. ** <italic>p</italic>&lt;0.01. Injection of saline did not change locomotor activity for either genotype (unpublished data). For 5 mg/kg <italic>N</italic> = 7 for control and 9 for VAChT<sup>D2-Cre-flox/flox</sup>. For 20 mg/kg <italic>N</italic> = 10 for control and 15 for VAChT<sup>D2-Cre-flox/flox</sup> mice. For 40 mg/kg <italic>N</italic> = 8.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g005" xlink:type="simple"/>
        </fig>
        <p>Cocaine increases firing of striatal cholinergic neurons <xref ref-type="bibr" rid="pbio.1001194-Witten1">[44]</xref> and the release of ACh in the striatum <xref ref-type="bibr" rid="pbio.1001194-Imperato1">[45]</xref>–<xref ref-type="bibr" rid="pbio.1001194-Williams1">[47]</xref>. Previous experiments have suggested that striatal cholinergic neurons also play important roles in the rewarding effects of cocaine. Indeed, optogenetic silencing of striatal cholinergic neurons seemed to attenuate the response of cocaine in a conditioned-place preference (CPP) paradigm. Because these experiments did not separate the contribution of ACh from that of glutamate and to determine if there was a causal link between ACh release and expression of cocaine-induced CPP, we performed CPP experiments with VAChT<sup>D2-Cre-flox/flox</sup> mice. We were unable to obtain reliable CPP with either genotype at 5 mg/kg of cocaine (unpublished data). In contrast, at 20 mg/kg we detected robust CPP in both genotypes (<xref ref-type="fig" rid="pbio-1001194-g006">Figure 6a</xref>, repeated measures ANOVAs show no effect of genotype, <italic>F</italic><sub>(1,10)</sub> = 0.443, <italic>p</italic> = 0.521, significant effect of treatment, <italic>F</italic><sub>(1,10)</sub> = 86.033, <italic>p</italic>&lt;0.001, and no Genotype × Treatment interaction, <italic>F</italic><sub>(1,10)</sub> = 0.0118, <italic>p</italic> = 0.916). In these experiments we used an extended protocol <xref ref-type="bibr" rid="pbio.1001194-Bohn1">[48]</xref> with consecutive injections of cocaine in alternate days. We repeated the short protocol used before in the optogenetic experiments <xref ref-type="bibr" rid="pbio.1001194-Witten1">[44]</xref> with only one injection of cocaine (20 mg/kg), but we were unable to detect place preference in control or VAChT<sup>D2-Cre-flox/flox</sup> mice (unpublished data). In addition, neither extinction of CPP nor relapse, measured as a reinstatement of CPP by a priming injection of cocaine after extinction, were altered in mice without striatal VAChT (<xref ref-type="fig" rid="pbio-1001194-g006">Figure 6b</xref>, repeated measures ANOVAs show no effect of genotype, <italic>F</italic><sub>(1,7)</sub> = 0.00057, <italic>p</italic> = 0.982, significant effect of treatment, <italic>F</italic><sub>(1,7)</sub> = 7.457, <italic>p</italic> = 0.029, and no Genotype × Treatment interaction, <italic>F</italic><sub>(1,7)</sub> = 9.67×10<sup>−5</sup>, <italic>p</italic> = 0.992). Therefore, there was no difference in CPP response for the two genotypes.</p>
        <fig id="pbio-1001194-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>CPP response of VAChT<sup>D2-Cre-flox/flox</sup> mice.</title>
            <p>(a) In the conditioning phase (days 2–7) mice received alternating injections of 20 mg/kg of cocaine or vehicle and were immediately confined into one of the two conditioning chambers for 30 min. The CPP response was measured on day 8, when the animals were allowed to move freely in the CPP apparatus and the time spent in each compartment was measured (<italic>N</italic> = 6). (b) Reinstatement to cocaine was tested after extinction of CPP by pairing of the cocaine paired chamber with saline injections. Once the extinction was acquired, a prime of 10 mg/kg of cocaine was injected and the animals re-exposed to the CPP apparatus. The time spent in each compartment was measured (<italic>N</italic> = 5). * <italic>p</italic>&lt;0.05, reinstatement versus extinction. *** <italic>p</italic>&lt;0.001, cocaine paired versus saline paired.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g006" xlink:type="simple"/>
        </fig>
        <p>Behavioural sensitization protocols for cocaine likely reflect altered synaptic plasticity in response to the drug <xref ref-type="bibr" rid="pbio.1001194-Robinson1">[49]</xref>, which manifests as an increase in the locomotor effects of cocaine. In a separate group of mice, we measured behavioural sensitization to 10 mg/kg of cocaine (<xref ref-type="fig" rid="pbio-1001194-g007">Figure 7</xref>) and found that repeated treatment with this dose of cocaine seems to cause slightly higher locomotor activity in VAChT<sup>D2-Cre-flox/flox</sup> mice, but the relative increase in behavioural sensitization was not different between genotypes (<xref ref-type="fig" rid="pbio-1001194-g007">Figure 7a,b</xref>, repeated measures ANOVAs show a significant effect of genotype, <italic>F</italic><sub>(1,16)</sub> = 4.902, <italic>p</italic> = 0.042, significant effect of treatment, <italic>F</italic><sub>(1,16)</sub> = 33.855, <italic>p</italic>&lt;0.001, and no Genotype × Treatment interaction, <italic>F</italic><sub>(1,16)</sub> = 0.496, <italic>p</italic> = 0.491). Thus, elimination of striatal ACh release caused a small change in the dose-response profile of cocaine-treated mice in intermediate doses: a slight increase in activity is observed at 10 mg/kg, whereas a decrease in locomotor response is observed at 20 mg/kg in mutant mice.</p>
        <fig id="pbio-1001194-g007" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g007</object-id>
          <label>Figure 7</label>
          <caption>
            <title>Behavioural sensitization to cocaine.</title>
            <p>(a) Repeated cocaine injections (10 mg/kg) promoted a progressive increase of locomotor sensitization (repeated measures ANOVAs show a significant effect of treatment, <italic>F</italic><sub>(1,16)</sub> = 33.855, <italic>p</italic>&lt;0.001). VAChT<sup>D2-Cre-flox/flox</sup> mice clearly manifested an enhancement in the locomotor activity in comparison with their control subjects (repeated measures ANOVAs show a significant effect of genotype, <italic>F</italic><sub>(1,16)</sub> = 4.902, * <italic>p</italic>&lt;0.05). (b) Cumulative 20 min locomotion after cocaine injection (10 mg/kg) of VAChT<sup>D2-Cre-flox/flox</sup> mice and controls (*** <italic>p</italic>&lt;0.001, day 6 versus day 1). Day 0 is the basal activity of the animals (no cocaine was injected).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g007" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2f">
        <title>VAChT<sup>D2-Cre-flox/flox</sup> Mice Have Increased Responses to Dopamine Agonists</title>
        <p>The balance between acetylcholine-dopamine is important in a number of conditions, including PD; therefore we further investigated dopaminergic function in VAChT<sup>D2-Cre-flox/flox</sup> mice. For that, we first determined the concentration of dopamine and metabolites in the striatum of VAChT<sup>D2-Cre-flox/flox</sup> mice and compared these to control mice. In general there were no major changes in dopamine and metabolites in these mutant mice (<xref ref-type="table" rid="pbio-1001194-t001">Table 1</xref>). However, the ratio between dopamine and DOPAC as well as dopamine and HVA were significantly changed, showing that dopamine turnover is decreased by 25% (<italic>p</italic>&lt;0.001), suggesting potential relatively minor alterations in dopamine dynamics or metabolism.</p>
        <table-wrap id="pbio-1001194-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pbio.1001194.t001</object-id><label>Table 1</label><caption>
            <title>Catecholamine content in the striatum (ng/100 mg of brain tissue).</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pbio-1001194-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.t001" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">NE</td>
                <td align="left" colspan="1" rowspan="1">DA</td>
                <td align="left" colspan="1" rowspan="1">DOPAC</td>
                <td align="left" colspan="1" rowspan="1">HVA</td>
                <td align="left" colspan="1" rowspan="1">DOPAC/DA</td>
                <td align="left" colspan="1" rowspan="1">HVA/DA</td>
                <td align="left" colspan="1" rowspan="1">(DOPAC+HVA)/DA</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">fx/fx</td>
                <td align="left" colspan="1" rowspan="1">20.400±1.515</td>
                <td align="left" colspan="1" rowspan="1">358.600±39.300</td>
                <td align="left" colspan="1" rowspan="1">31.480±3.523</td>
                <td align="left" colspan="1" rowspan="1">58.140±5.205</td>
                <td align="left" colspan="1" rowspan="1">0.088±0.001</td>
                <td align="left" colspan="1" rowspan="1">0.164±0.004</td>
                <td align="left" colspan="1" rowspan="1">0.250±0.006</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">D2-Cre-fx/fx</td>
                <td align="left" colspan="1" rowspan="1">27.800±1.878*</td>
                <td align="left" colspan="1" rowspan="1">365.400±27.570</td>
                <td align="left" colspan="1" rowspan="1">25.160±1.780</td>
                <td align="left" colspan="1" rowspan="1">48.540±3.236</td>
                <td align="left" colspan="1" rowspan="1">0.069±0.002*</td>
                <td align="left" colspan="1" rowspan="1">0.134±0.004*</td>
                <td align="left" colspan="1" rowspan="1">0.200±0.004*</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt101">
              <label/>
              <p>HPLC analysis of supernatant samples of striatum from VAChT<sup>D2-Cre-flox/flox</sup> and control mice (<italic>n</italic> = 5). The samples were analyzed for norepinephrine (NE), dopamine (DA), and its two metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) by NoAb BioDiscoveries. * <italic>p</italic>&lt;0.05.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <p>To further assess dopaminergic function, we performed qPCR analysis for D1R and D2R expression in the striatum. We detected an increase in the expression of D1R and D2R mRNAs in the striatum of VAChT<sup>D2-Cre-flox/flox</sup> mice compared to control mice (<xref ref-type="fig" rid="pbio-1001194-g008">Figure 8a and b</xref>, D1R, <italic>t</italic><sub>(12)</sub> = 2.756, <italic>p</italic>&lt;0.05, D2R, <italic>t</italic><sub>(14)</sub> = 2.300, <italic>p</italic>&lt;0.05). In contrast, D2R mRNA expression in the midbrain was not altered (<xref ref-type="fig" rid="pbio-1001194-g008">Figure 8c</xref>). G-protein coupled receptors (GPCRs) can have agonist-independent effects; hence, altered expression of such receptors could modulate behaviour even in the absence of neurotransmitter release. We thus also investigated the expression of cholinergic receptors. <xref ref-type="fig" rid="pbio-1001194-g008">Figure 8d–f</xref> indicates that expression of M1 and M2 muscarinc receptors (mAChR1 and mAChR2) was unchanged, whereas M4 muscarinic receptors (mAChR4) showed increased expression (<italic>t</italic><sub>(12)</sub> = 3.678, <italic>p</italic>&lt;0.05). Homozygous mice expressing D2-BAC-GFP construct present some dopaminergic phenotypes <xref ref-type="bibr" rid="pbio.1001194-Kramer1">[50]</xref>, however control experiments show that the heterozygous D2-Cre mice used here do not present any of the phenotypes associated with selective elimination of striatal VAChT (<xref ref-type="supplementary-material" rid="pbio.1001194.s006">Figure S6</xref>). Because dopamine receptor expression was normal in D2-Cre mice, we conclude that these molecular alterations are due to the loss of ACh release.</p>
        <fig id="pbio-1001194-g008" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g008</object-id>
          <label>Figure 8</label>
          <caption>
            <title>Expression of dopamine and acetylcholine muscarinic receptors in VAChT<sup>D2-Cre-flox/flox</sup> mice.</title>
            <p>(a) D1R mRNA expression in striatum, (b) D2R mRNA expression in striatum, (c) D2R mRNA expression in the midbrain, (d) M1 mRNA expression in striatum, (e) M2 mRNA expression in striatum, and (f) M4 mRNA expression in striatum. * <italic>p</italic>&lt;0.05 and ** <italic>p</italic>&lt;0.01.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g008" xlink:type="simple"/>
        </fig>
        <p>To confirm the increased alteration of dopamine receptors in the striatum of VAChT<sup>D2-Cre-flox/flox</sup> mice we initially performed Western blots. Unfortunately, we were unable to obtain a reliable D1 antibody that showed specific detection of D1R (unpublished data). However, we obtained a D2 antibody that labelled only one major band with the correct molecular mass (<xref ref-type="fig" rid="pbio-1001194-g009">Figure 9a</xref>). Quantification of immunoblots confirmed increased expression of D2R (<xref ref-type="fig" rid="pbio-1001194-g009">Figure 9a,b,</xref> <italic>t</italic><sub>(14)</sub> = −3.628, <italic>p</italic>&lt;0.01). In order to provide an independent measure of D1R activity and test if D1-mediated responses would be altered in VAChT-eliminated mice, we used pharmacological magnetic resonance imaging (<italic>ph</italic>MRI) <xref ref-type="bibr" rid="pbio.1001194-Nguyen1">[51]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Delfino1">[52]</xref>. <italic>ph</italic>MRI is a variant of functional magnetic resonance imaging that indirectly detects neuronal activity using blood oxygenation level-dependent (BOLD) MRI signal changes <xref ref-type="bibr" rid="pbio.1001194-Ogawa1">[53]</xref> to detect functional effects of pharmacological agents in intact systems in vivo with high temporal and spatial resolution. A 9.4T anatomic MRI of the mouse brain (<xref ref-type="fig" rid="pbio-1001194-g009">Figure 9c</xref>) was used to outline regions of interest in the striatum and cortex. The average difference in BOLD effect between striatum and cortex (<xref ref-type="fig" rid="pbio-1001194-g009">Figure 9d</xref>) indicates that there is increased neuronal activation in the striatum in VAChT<sup>D2-Cre-flox/flox</sup> mice following injection of SFK 81297 (3 mg/kg, <xref ref-type="fig" rid="pbio-1001194-g009">Figure 9d</xref>). The change in the BOLD response after administration of the selective D1R agonist SKF 81297 relative to baseline (prior to injection) was then compared between the two genotypes. Saline administration prior to SKF 81297 did not alter BOLD signal (unpublished data). In contrast, injection of SKF 81297 lead to a slow increase in striatal BOLD response (area under the curve) in VAChT<sup>D2-Cre-flox/flox</sup> mice compared to control mice following injection of the D1R agonist (<xref ref-type="fig" rid="pbio-1001194-g009">Figure 9d and e</xref>, <italic>p</italic>&lt;0.01).</p>
        <fig id="pbio-1001194-g009" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g009</object-id>
          <label>Figure 9</label>
          <caption>
            <title>Increased dopamine receptor expression and activity in VAChT<sup>D2-Cre-flox/flox</sup> mice.</title>
            <p>(a) Striatal D2R protein levels inVAChT<sup>D2-Cre-flox/flox</sup> mice and controls (<italic>n</italic> = 8). * <italic>p</italic>&lt;0.05. (b) D2R representative immunoblot blot. (c) Axial MRI FLASH image (500 μm thick) through the striatum (outlined region 1) and cerebral cortex (outlined region 2). (d) Average BOLD signal change in the striatum relative to cerebral cortex prior to and following injection of SFK 81297 at time zero (black arrow). Signal response for VAChT<sup>D2-Cre-flox/flox</sup> mice (<italic>N</italic> = 5) is shown with black triangles, and response for control mice (<italic>N</italic> = 4) is shown with open squares. Error bars represent the standard error of the mean. (e) Area under the curve for VAChT<sup>D2-Cre-flox/flox</sup> mice (<italic>N</italic> = 5) is shown with black triangles, and response for control mice (<italic>N</italic> = 4) is shown with open squares. The difference between genotypes was statistically significant (<italic>p</italic>&lt;0.01).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g009" xlink:type="simple"/>
        </fig>
        <p>To test if the increased expression/sensitivity of D1R and D2R has direct behavioural consequences, we investigated the effects of the selective dopaminergic agonists SKF 81297 (D1R agonist) and quinpirole (D2R agonist) on locomotor activity. VAChT<sup>D2-Cre-flox/flox</sup> mice had significantly higher locomotor responses to two doses of SKF 81297 (<xref ref-type="fig" rid="pbio-1001194-g010">Figure 10a and b</xref>, two-factor ANOVAs revealed significant effect of genotype, <italic>F</italic><sub>(1,66)</sub> = 11.654, <italic>p</italic>&lt;0.01, significant effect of drug concentration, <italic>F</italic><sub>(3,66)</sub> = 34.476, <italic>p</italic>&lt;0.001, and significant Drug Concentration × Genotype interaction, <italic>F</italic><sub>(3,66)</sub> =  4.277, <italic>p</italic>&lt;0.01, Tukey post hoc test showed significant differences with SKF 81297 doses of 3 mg/kg (<italic>p</italic>&lt;0.01) and 8 mg/kg (<italic>p</italic>&lt;0.001)). Moreover, VAChT<sup>D2-Cre-flox/flox</sup> mice also showed enhanced inhibition of locomotion in response to low doses of the D2R-selective agonist quinpirole (<xref ref-type="fig" rid="pbio-1001194-g010">Figure 10c and d</xref>, ANOVA showed significant effect of genotype, <italic>F</italic><sub>(1,111)</sub> = 12.543, <italic>p</italic>&lt;0.001, significant effect of drug, <italic>F</italic><sub>(4,111)</sub> = 42.223, <italic>p</italic>&lt;0.001, but the interaction was not significant, <italic>F</italic><sub>(4,111)</sub> = 2.052, <italic>p</italic> = 0.092). Analysis of locomotion in response to the individual doses showed a significant difference for 0.005 and for 0.01 mg/kg quinpirole dose (<italic>p</italic>&lt;0.01). Taken together, these data reveal important alterations in the expression and function of striatal dopamine receptors in VAChT<sup>D2-Cre-flox/flox</sup> mice.</p>
        <fig id="pbio-1001194-g010" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pbio.1001194.g010</object-id>
          <label>Figure 10</label>
          <caption>
            <title>Effect of D1R or D2R agonists on locomotor activity in VAChT<sup>D2-Cre-flox/flox</sup> mice.</title>
            <p>(a) Effect of injection of SFK 81297 (3 mg/kg) 20 min after the mice were introduced to the open field, (b) dose-response for SKF 81297, (c) effect of quinpirole (0.01 mg/kg) as in (a), and (d) dose response for quinpirole. * <italic>p</italic>&lt;0.05, ** <italic>p</italic>&lt;0.01, and *** <italic>p</italic>&lt;0.001. <italic>N</italic> = 10 and 13 for saline, SKF 81297 <italic>N</italic> = 7 and 5 for 0.5 mg/kg, <italic>N</italic> = 9 and 4 for 3 mg/kg, and <italic>N</italic> = 7 and 9 for 8 mg/kg. For quinpirole <italic>N</italic> = 7 and 13 for 0.005 mg/kg, <italic>N</italic> = 17 and 15 for 0.01 mg/kg, <italic>N</italic> = 11 and 12 for 0.1 mg/kg, and <italic>N</italic> = 11 and 13 for 6 mg/kg for control and VAChT<sup>D2-Cre-flox/flox</sup> mice, respectively.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.g010" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>Here we present a series of evidence that delineates the role of released ACh from those of VGLUT3-dependent glutamate release from striatal cholinergic interneurons. Our data provide a novel perspective on the function of striatal cholinergic neurons suggesting the possibility that they can use distinct neurotransmitters to regulate striatal circuitry. We found that elimination of VAChT in the striatum, without disruption of VGLUT3, did not cause overt disruptions or alterations in several behavioural tasks previously thought to be dependent on striatal ACh release, such as motor learning, sensorimotor gating, and spontaneous locomotor activity. However, we uncovered a novel form of regulation of MSNs by cholinergic tone, and found that selective silencing of striatal ACh release results in an increase in the responses to D1R and D2R agonists. In contrast to the effects of direct dopamine receptor agonists, we found that overall these mice do not show increased locomotor response to cocaine. Similarly, sensitization and rewarding effects of cocaine did not seem to be dependent on striatal release of ACh. Thus, our results significantly depart from previous studies in which the specific contributions of striatal ACh release (mediated by VAChT) were not separated from those of glutamate release (mediated by VGLUT3). These data suggest that VGLUT-3 dependent glutamate release may influence locomotor activity and responses to cocaine considerably more than VAChT-dependent ACh release. Our data suggest that targeted approaches aimed at inhibiting VAChT activity in the striatum may potentially provide a novel strategy to enhance dopaminergic signalling, without causing other major behavioural disturbances.</p>
      <sec id="s3a">
        <title>VAChT<sup>D2-cre-flox/flox</sup> Mice Have Normal Motor Performance, Sensorimotor Gating, and Motor Learning</title>
        <p>Our studies in VAChT<sup>D2-cre-flox/flox</sup> mice indicated that elimination of ACh release in the striatum does not seem to play a major role in motor function and motor learning, at least for acrobatic motor skills in the rotarod test. This observation is also in agreement with previous experiments in striatal cholinergic neuron-ablated mice that presented no deficiency in rotarod performance <xref ref-type="bibr" rid="pbio.1001194-Kitabatake1">[31]</xref>. However, we cannot completely exclude more subtle effects of ACh in fine motor tuning and motor tasks. For example, the chronic nature of elimination of ACh release in our experiments may lead to adaptations in motor behaviour. Future experiments using VAChT<sup>D2-Cre-flox/flox</sup> mice and more sophisticated motor behavioural tests may be necessary to pinpoint possible roles for striatal ACh in motor learning and performance.</p>
        <p>There are multiple lines of evidence that pharmacological modulation of cholinergic receptors regulates locomotor activity. It is known that muscarinic antagonists increase locomotor activity and M1 and M4 muscarinic receptor KO mice are hyperactive <xref ref-type="bibr" rid="pbio.1001194-Miyakawa1">[54]</xref>–<xref ref-type="bibr" rid="pbio.1001194-Jeon1">[57]</xref>. Moreover, we have recently observed that mice with a significant decrease in VAChT expression in the whole forebrain show hyperactivity <xref ref-type="bibr" rid="pbio.1001194-MartinsSilva1">[32]</xref>. The present work provides compelling evidence for more selective roles of the neurotransmitter ACh in the striatum, indicating that decreased striatal expression of VAChT does not cause overt motor consequences. These results may be of particular importance, since there have been reports that in Huntington's disease VAChT levels are decreased in the striatum <xref ref-type="bibr" rid="pbio.1001194-Smith1">[58]</xref>. Our data suggest, however, that this alteration is unlikely to contribute to gross motor symptoms observed in Huntington's disease. Cholinergic neurotransmission in brain regions other than the striatum may still play a role in control of locomotion.</p>
        <p>Previous attempts to assess the function of cholinergic neurons in the striatum were performed following the ablation of cholinergic neurons using immunotoxin-mediated cell targeting. Injection of toxin targeting transgenic cholinergic neuron in the accumbens led to an 80% decrease in ChAT-positive neurons <xref ref-type="bibr" rid="pbio.1001194-Kaneko1">[30]</xref>. Elimination of cholinergic neurons in the accumbens by this means inhibited certain forms of reward-related learning; however, it also induced hyperactivity and increased sensitivity to the locomotor and the rewarding effects of cocaine, including increased sensitivity in the CPP test to low doses of cocaine <xref ref-type="bibr" rid="pbio.1001194-Hikida1">[28]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Hikida2">[29]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Kitabatake1">[31]</xref>. In contrast, recent experiments using an optogenetic approach to inactivate or activate cholinergic neurons in the accumbens found no effects of inactivation of these neurons on locomotor activity, albeit their silencing prevented the response to cocaine in a CPP test <xref ref-type="bibr" rid="pbio.1001194-Witten1">[44]</xref>. Thus, elimination of cholinergic neurons in the accumbens seemed to increase sensitivity to cocaine-induced CPP <xref ref-type="bibr" rid="pbio.1001194-Hikida2">[29]</xref>, whereas optogenetics silencing of these neurons blocked cocaine-induced CPP <xref ref-type="bibr" rid="pbio.1001194-Witten1">[44]</xref>. The reason for the different outcome in these two experiments is not entirely clear at the moment, but could be related to the chronic versus acute nature of the manipulations. Although in our experiments we have targeted the whole striatum, rather than only the accumbens, we did not detect major alterations in cocaine-induced CPP, suggesting that the above effects obtained with neuronal ablation or by optogenetics manipulation may be linked not to loss of cholinergic transmission per se but rather to suppression of glutamate release from cholinergic neurons.</p>
        <p>While an optogenetic approach provides a novel paradigm to acutely activate or inactivate populations of neurons, it is unlikely that this method can separate VAChT from VGLUT3-dependent neurotransmission as selectively as that which can be achieved using VAChT<sup>D2-Cre-flox/flox</sup> mice. Interestingly, recent data have shown that cholinergic neurons in the habenula secrete both ACh and glutamate (mediated by VGLUT1), and release of either of these neurotransmitters appears to depend on the frequency of stimulation <xref ref-type="bibr" rid="pbio.1001194-Ren1">[22]</xref>. Basal forebrain neurons in culture release both ACh and glutamate <xref ref-type="bibr" rid="pbio.1001194-Allen1">[59]</xref>. Importantly, recent work shows that optogenetics stimulation of striatal cholinergic neurons can evoke synaptic glutamatergic neurotransmission onto MSNs, with predominant activity over NMDA receptors <xref ref-type="bibr" rid="pbio.1001194-Higley1">[27]</xref>. The co-release of glutamate with dopamine has also been described <xref ref-type="bibr" rid="pbio.1001194-Hnasko1">[60]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Stuber1">[61]</xref>, suggesting that interpretation of the roles of dopaminergic neurons will also need to take into account glutamate co-release. Therefore, the co-release of glutamate with classical neurotransmitters may be a more common mechanism than previously appreciated and may have a broad impact in circuitry control. However, we cannot discard the possibility that other neuromodulators released from cholinergic neurons, such as ATP or peptides, could also play a role as co-transmitters.</p>
        <p>The role of VGLUT3 in striatal function is far from being fully understood <xref ref-type="bibr" rid="pbio.1001194-ElMestikawy1">[62]</xref>. Interestingly, with respect to striatum-related behaviour, VGLUT3-null mice show hyperactivity and increased response to the locomotor effects of cocaine <xref ref-type="bibr" rid="pbio.1001194-Gras1">[25]</xref>. Therefore, mice lacking VGLUT3 show a phenotype that is remarkably similar to that of mice in which cholinergic neurons in the accumbens were targeted by an immunotoxin <xref ref-type="bibr" rid="pbio.1001194-Hikida2">[29]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Kaneko1">[30]</xref>. Experiments in VGLUT3-null mice suggested that the absence of VGLUT3 causes a decrease in striatal cholinergic tone. VGLUT3 is used by the striatal vesicles to facilitate VAChT-mediated ACh storage in synaptic vesicles <xref ref-type="bibr" rid="pbio.1001194-Gras1">[25]</xref>,<xref ref-type="bibr" rid="pbio.1001194-ElMestikawy1">[62]</xref>. However, measurements of ACh release in VGLUT3-null mice have indicated only a modest reduction, by 30% to 40% <xref ref-type="bibr" rid="pbio.1001194-Gras1">[25]</xref>, compared to almost 100% inhibition in VAChT<sup>D2-Cre-flox/flox</sup> mice. It is unlikely that 40% reduction in ACh release observed in VGLUT3-null mice can be responsible for the hyperactive phenotype. Indeed, independent mouse lines with a 50% decrease in VAChT expression, and concomitant reduction of ACh release <xref ref-type="bibr" rid="pbio.1001194-deCastro1">[16]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>,<xref ref-type="bibr" rid="pbio.1001194-LimaRde1">[63]</xref>, did not present increased locomotor activity in the open field <xref ref-type="bibr" rid="pbio.1001194-deCastro1">[16]</xref>,<xref ref-type="bibr" rid="pbio.1001194-deCastro2">[35]</xref>. We conclude that the locomotor phenotypes observed previously in striatal cholinergic neuron-ablated mice <xref ref-type="bibr" rid="pbio.1001194-Hikida2">[29]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Kitabatake1">[31]</xref> and in VGLUT3-null mice <xref ref-type="bibr" rid="pbio.1001194-Gras1">[25]</xref> are either a consequence of the disruption of VGLUT3-mediated neurotransmission or the combination of reducing both glutamatergic and cholinergic activity simultaneously from these neurons. Future experiments using VAChT<sup>D2-Cre-flox/flox</sup> mice, VGLUT3 floxed mice, and double knockouts will be necessary to provide an assessment of independent effects of VGLUT3-mediated neurotransmission in the striatum.</p>
        <p>Although we have focused on striatal-related behaviours, the extent by which alterations in VAChT expression in other brain regions in VAChT<sup>D2-cre-flox/flox</sup> mice may contribute to these phenotypes should also be taken into account. We did not detect Cre-expression in cholinergic neurons in the penduculopontine area, for example (<xref ref-type="supplementary-material" rid="pbio.1001194.s002">Figure S2</xref>), which harbours groups of cholinergic neurons that project to the midbrain and thalamus and could influence striatal function. However, we cannot completely exclude the possibility that cholinergic neurons in other brain regions would not be targeted in our mouse line. At the same time, as the phenotypes described here seem to be mainly striatal specific and cholinergic interneurons provide the almost exclusive source of cholinergic tone in the striatum, it is unlikely that other groups of cholinergic neurons would have contributed to the observed behaviours.</p>
        <p>Elimination of cholinergic neurotransmission in the striatum did not cause hyperlocomotion, however the responses to direct activation of dopamine receptors were substantially increased. Both behavioural and <italic>ph</italic>MRI analysis indicated an increased response to D1R agonist. Western blot analysis also showed selective increase of D2R expression in the striatum. Moreover, in addition to the increased D2R levels in the striatum, which likely reflect a combination of pre- and post-synaptic receptors, we also uncovered increased D2-like receptor pre-synaptic activity, revealed by the increased sensitivity of VAChT<sup>D2-Cre-flox/flox</sup> mice to low doses of quinpirole. Certainly, we cannot rule out that changes at the level of receptors play a more complex role in regulating locomotor activity in VAChT<sup>D2-Cre-flox/flox</sup> mice. Indeed, GPCRs may have agonist-independent activity <xref ref-type="bibr" rid="pbio.1001194-Spalding1">[64]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Galandrin1">[65]</xref>. The locomotor effects of cocaine seem to depend mainly on inhibition of the dopamine transporter <xref ref-type="bibr" rid="pbio.1001194-Giros1">[66]</xref>. However, acetylcholine can affect release of dopamine via distinct nicotinic receptors <xref ref-type="bibr" rid="pbio.1001194-Zhou2">[19]</xref>, as well as regulate both dopamine release and activity of MSNs, via distinct muscarinic receptors <xref ref-type="bibr" rid="pbio.1001194-Gomeza1">[56]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Jeon1">[57]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Bonsi1">[67]</xref>. The fact that both D1R and D2R had increased expression in the striatum would suggest that VAChT<sup>D2-Cre-flox/flox</sup> mice should be more responsive to dopamine and might present increased spontaneous locomotor activity or cocaine-induced locomotion or CPP. However, this was not the case. It is likely that cell-autonomous compensatory mechanisms related to disrupted cholinergic function significantly altered striatal circuitry, preventing such a simple relationship. For example, because M4 muscarinic receptors seem to specifically regulate D1R-mediated signalling <xref ref-type="bibr" rid="pbio.1001194-Gomeza1">[56]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Jeon1">[57]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Guo1">[68]</xref>, it is possible that the increased expression of M4 receptors we detected in the striatum could counterbalance D1R-mediated responses in vivo, leading to unaltered locomotor activity. Moreover, because D2-like pre-synaptic receptors may be more active in VAChT<sup>D2-Cre-flox/flox</sup> mice, elimination of ACh release in the striatum may also affect pre-synaptic control of dopamine release. The slightly decreased turnover of dopamine in mice without striatal VAChT supports the notion of direct consequences of reduced cholinergic tone at the level of dopaminergic terminals. Thus, behavioural analysis of VAChT<sup>D2-Cre-flox/flox</sup> mice indicates that control of locomotor function and response to cocaine mediated by dopamine might become more complex in the absence of cholinergic tone. Future experiments will be needed to evaluate direct consequences of elimination of either acetylcholine or glutamate neurotransmission originating from striatal cholinergic neurons on dopamine transmission.</p>
      </sec>
      <sec id="s3b">
        <title>Conclusion</title>
        <p>The present data provide direct and indirect evidence that striatal cholinergic neurons can use two different neurotransmitters to regulate striatal function. Hence, re-evaluation of previously attributed functions of striatal cholinergic tone is warranted. The data indicate that VGLUT3-mediated glutamatergic neurotransmission originating from cholinergic neurons may have greater influence on striatal function than previously envisioned. The behavioural consequences of selective elimination of VAChT, and thus cholinergic transmission, in the striatum are remarkably minimal, at least for the locomotion control by the striatal complex. One intriguing phenotype uncovered in mutant mice is an increase in dopamine receptors' expression and function without major alterations in cocaine-induced behaviours. Our experiments provide evidence that targeting VAChT in the striatum can up-regulate dopamine receptors and thus could be used in conditions of dopamine deficiency and abnormally increased cholinergic activity, as found in individuals with PD.</p>
      </sec>
    </sec>
    <sec id="s4" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s4a">
        <title>Animals</title>
        <p>The isolation of a VAChT genomic clone has been described previously <xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>. The genomic clone was used to construct a gene-targeting vector in which we added LoxP sequences flanking the VAChT open reading frame and a TK-Neo cassette. Generation of VAChT<sup>flox/flox</sup> mice is described elsewhere <xref ref-type="bibr" rid="pbio.1001194-MartinsSilva1">[32]</xref>, and the construct is shown in <xref ref-type="supplementary-material" rid="pbio.1001194.s002">Figure S2</xref>. Briefly, after removal of the TK-Neo cassette, one LoxP sequence was present 260 bp upstream from the VAChT translational initiation codon, and a second LoxP sequence was located approximately 1.5 kb downstream from the VAChT stop codon and within the second ChAT intron. Note that this vector is distinct from that previously used for generation of VAChT KD mice <xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>.</p>
        <p>D2-Cre mice (Drd2, Line ER44) were obtained from the GENSAT project via the mutant mouse regional resource centers. VAChT<sup>D2-Cre-flox/flox</sup> mice were generated by crossing VAChT<sup>flox/flox</sup> with the D2-Cre mouse line. We then inter-crossed VAChT<sup>D2-Cre-flox/wt</sup> to obtain VAChT<sup>D2-Cre-flox/flox</sup> mice. Because these mice were apparently normal and fertile, we bred VAChT<sup>D2-Cre-flox/flox</sup> mice and VAChT<sup>flox/flox</sup> to obtain all the mice used in the present study. These mice were backcrossed to C57BL/6J mice for five generations. Unless otherwise stated, all control mice used were VAChT<sup>flox/flox</sup> littermate mice without the Cre transgene.</p>
        <p>After the completion of this work we were made aware that the BAC used to generate D2-Cre mice carried an extra gene, <italic>ttc2</italic>, and a recent report suggests that homozygous D2-GFP mice, generated using the same BAC construct, are hyperactive and show a number of dopamine-related phenotypes <xref ref-type="bibr" rid="pbio.1001194-Kramer1">[50]</xref>. However, as these authors point out, their experiments cannot discern if the phenotypes uncovered are due to the BAC positioning insertion or to the extra copy of <italic>ttc2.</italic> We confirmed that the D2-Cre indeed have increased expression of the TTC2 mRNA (unpublished data). However, heterozygous D2-Cre mice showed no locomotor phenotype. Moreover, these mice showed normal levels of D1R, D2R, and M4-muscarinic receptors (<xref ref-type="supplementary-material" rid="pbio.1001194.s006">Figure S6</xref>). Hence, neither the phenotypes nor the molecular changes observed in VAChT<sup>D2-Cre-flox/flox</sup> mice are due to the BAC transgene.</p>
        <p>Rosa26-YFP mice (B6.129X1-Gt(ROSA)26Sor<sup>tm1(EYFP)Cos/J</sup>, stock number 006148) were obtained from Jackson Laboratories. Animals were housed in groups of three to four mice per cage without environment enrichment in a temperature-controlled room with 12-h light–12-h dark cycles, and food and water were provided ad libitum. Mouse stocks were SPF, however experimental subjects were kept in a conventional mouse facility.</p>
      </sec>
      <sec id="s4b">
        <title>Ethics Statement</title>
        <p>All studies were conducted in accordance with the NIH and the Canadian Council of Animal Care (CCAC) guidelines for the care and use of animals with approved animal protocol from the Institutional Animal Care and Use Committees at the University of Western Ontario (protocol number 2008–089). Only male mice were used for the behavioural studies, and they were at least 12 weeks old. Mice were randomly assigned to distinct experimental groups. Only mice used for evaluation of spontaneous locomotor behaviour were used in other tasks.</p>
      </sec>
      <sec id="s4c">
        <title>Immunofluorescence, qPCR, and Western Blot</title>
        <p>For the immunofluorescence experiments we followed a protocol previously described <xref ref-type="bibr" rid="pbio.1001194-deCastro2">[35]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Ferreira1">[69]</xref>. For mRNA analyses tissue samples were frozen in a mixture of dry ice/ethanol and kept at −80°C until used as described <xref ref-type="bibr" rid="pbio.1001194-Lara1">[70]</xref>. Immunoblotting was performed as described elsewhere <xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Ribeiro2">[71]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Ribeiro3">[72]</xref>.</p>
      </sec>
      <sec id="s4d">
        <title>Measurements of [<sup>3</sup>H]ACh Release from Brain Slices</title>
        <p>Slices were obtained from the striatum and hippocampus of control and test mice, labelled with [<sup>3</sup>H]methyl-choline, and the release of labelled ACh was determined essentially as described <xref ref-type="bibr" rid="pbio.1001194-Barbosa1">[73]</xref> except that 33 mM KCl was used as a depolarizing stimuli.</p>
      </sec>
      <sec id="s4e">
        <title>Preparation of Synaptosomes and Glutamate Release</title>
        <p>Striatal synaptosomes were prepared by the method of <xref ref-type="bibr" rid="pbio.1001194-Dunkley1">[74]</xref>,<xref ref-type="bibr" rid="pbio.1001194-Dunkley2">[75]</xref> as previously described <xref ref-type="bibr" rid="pbio.1001194-Prado2">[76]</xref>. Glutamate release was followed continuously using a fluorimetric method <xref ref-type="bibr" rid="pbio.1001194-Nicholls1">[77]</xref> exactly as previously described <xref ref-type="bibr" rid="pbio.1001194-Guatimosim1">[78]</xref>.</p>
      </sec>
      <sec id="s4f">
        <title>Measurements of Locomotor Activity</title>
        <p>All behavioural experiments were performed between 9 a.m. and 4 p.m. in the light cycle, essentially as previously described <xref ref-type="bibr" rid="pbio.1001194-deCastro1">[16]</xref>,<xref ref-type="bibr" rid="pbio.1001194-deCastro2">[35]</xref> except the spontaneous activity of the first hours of the dark cycle was done from 7 p.m. to 10 p.m.</p>
      </sec>
      <sec id="s4g">
        <title>Catecholamine Measurement</title>
        <p>The dissected brain tissues were homogenized in 0.2 M perchloric acid with 100 µM EDTA-2Na. Samples were spun in a microcentrifuge at 12,000 rpm for 15 min at 4°C. Samples of the supernatant were then analyzed for norepinephrine (NE), dopamine (DA), and its two metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) by NoAb BioDiscoveries (Mississauga, ON).</p>
        <p>The HPLC used was an Eicom EP-700 with electrochemical detection (Eicom ECD-700). To elute catecholamines from the reverse phase column (3.0×100 mm SC-3ODS column, Eicom), a mobile phase consisting of 0.1 M citric acetate buffer pH 3.5 with 5 mg/ml EDTA-2Na, 220 mg/L sodium octane sulfonate, and 22% methanol was used.</p>
      </sec>
      <sec id="s4h">
        <title>Acoustic Startle Measurements</title>
        <p>These experiments have been described in <xref ref-type="bibr" rid="pbio.1001194-Schmid1">[79]</xref>. Briefly, animals were acclimatized 3–5 times to the startle boxes (Med Associates). Habituation of startle was measured using 30 startle pulses (20 ms, white noise, 115 dB on a 65 bd white noise background) with an inter-trial interval of 20 s. Subsequently, prepulse inhibition was measured by displaying 50 startle stimuli with either no prepulse (pulse alone), a 75 dB (4 ms white noise) prepulse preceding the pulse by either 30 ms or 100 ms, or a 85 db prepulse (30 ms or 100 ms interval). Each of the five trial types were displayed 10 times in a pseudorandomized order. PPI is expressed as the average startle response to the respective prepulse trials in relation to the pulse alone trials.</p>
      </sec>
      <sec id="s4i">
        <title>Grip-Force and Wire-Hang</title>
        <p>A Grip Strength Meter from Columbus Instruments (Columbus, OH) was used to measure forelimb grip strength essentially as described <xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>. For the wire-hang test each mouse was placed on a metal wire-grid, which was slowly inverted and suspended 40 cm above a piece of foam as previously described <xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>. The time it took for each mouse to fall from the cage top was recorded with a 60 s cut-off.</p>
      </sec>
      <sec id="s4j">
        <title>Rotarod</title>
        <p>The rotarod task followed a previously described protocol <xref ref-type="bibr" rid="pbio.1001194-Prado1">[36]</xref>.</p>
      </sec>
      <sec id="s4k">
        <title>CPP</title>
        <p>The CPP protocol was modified from <xref ref-type="bibr" rid="pbio.1001194-Brown1">[80]</xref>. Briefly, CPP was performed in a three chamber apparatus containing two large compartments with differences in visual and tactile cues, separated by a neutral area. In day 1 (habituation), mice were placed in the central compartment and allowed free access to the entire apparatus for 30 min. The time spent in each compartment was recorded. On days 2–7 (the conditioning phase), mice received alternating injections of cocaine or vehicle and were immediately confined into one of the two large compartments for 30 min. A combination of unbiased and biased allocation was used. On day 8 (test day) mice were once again allowed free access to all three compartments for 30 min, and the time spent in each compartment was recorded. For the CPP extinction and reinstatement, the protocol previously described <xref ref-type="bibr" rid="pbio.1001194-Brown1">[80]</xref> was followed.</p>
      </sec>
      <sec id="s4l">
        <title>Behavioural Sensitization</title>
        <p>Behavioural sensitization was performed as described <xref ref-type="bibr" rid="pbio.1001194-Jeon1">[57]</xref>.</p>
      </sec>
      <sec id="s4m">
        <title>Object Recognition Memory</title>
        <p>The general procedure was previously described, but for analysis we used Anymaze <xref ref-type="bibr" rid="pbio.1001194-deCastro2">[35]</xref>.</p>
      </sec>
      <sec id="s4n">
        <title>Pharmacological Magnetic Resonance Imaging (<italic>ph</italic>MRI)</title>
        <p>Mice (VAChT<sup>D2-cre/flox/flox</sup>, <italic>N</italic> = 5; control, <italic>N</italic> = 4) were anesthetized with 4% isofluorane and maintained at 1.5% isoflurane during the MRI scanning. Two intraperitoneal (I.P.) catheters (26 gauge, Abbotcath) were used for injection of saline and SFK. The catheters were secured in place with subcutaneous sutures. Catheters were connected to polyethelyne tubing (PE50, VWR, Canada) and to syringes containing saline and SFK for remote injection during imaging. Mice were placed in a custom built frame designed to secure the skull and minimize respiration induced movement during image acquisition. Mice were imaged on a 9.4 Tesla small animal MRI scanner (Agilent, Palo Alto, CA) equipped with a two-channel surface coil (diameter  = 2 cm). A fast low angle shot (FLASH) pulse sequence was used to acquire anatomical images (field of view  = 19.2×19.2 mm<sup>2</sup>, matrix  = 128×128, repetition time  = 50 ms, echo time  = 11 ms, flip angle  = 11°, and 10 averages). Respiratory gated lower resolution FLASH images were also acquired for pharmacological imaging (field of view  = 19.2×19.2 mm<sup>2</sup>, data matrix  = 64×64, repetition time  = 15 ms, echo time  = 7 ms, flip angle  = 11°, and 1 average) to measure blood oxygen level–dependent (BOLD) signal changes. Seven contiguous axial slices (500 μm thick) covered the brain. Each animal received two injections: first, an injection of 0.5 ml physiological saline (0.9%) administered over a 30 s period (control), and second, SFK 81297 (3 mg/kg), diluted in 0.5 ml physiological saline, also administered over a 30 s period (drug). For the control experiment, images were acquired for 8 min prior to saline injection and then for 20–50 min following injection. For the drug experiment, images were acquired for 8 min prior to drug injection and then for 80–180 min after injection. Throughout the imaging session, body temperature and respiration rate was monitored every 10 min using the MR-Compatible, Model 1025 monitoring system (Small Animal Instruments Inc., Stony Brook, NY). Temperature was maintained at 37.5°C using a warm air blower, and respiration rate ranged from 45–66 (mean 54 BPM). Following imaging, mice were euthanized by cervical dislocation while still under isoflurane anaesthesia.</p>
        <p>To limit the influence of global motion on the functional result, the signal intensity difference between striatum and cortex was used to examine the effect of SFK 81297 on the striatum as a function of time. A single slice transecting the striatum was chosen for analysis in each animal (<xref ref-type="fig" rid="pbio-1001194-g009">Figure 9c</xref>). BOLD signal change was expressed as the percentage change relative to the average baseline signal (first 50 images) prior to drug injection.</p>
      </sec>
      <sec id="s4o">
        <title>Statistical Analysis</title>
        <p>Data are expressed as mean ± SEM. Sigmastat 3.1 software was used for statistical analysis. Comparison between two experimental groups was done by Student's <italic>t</italic> test or Mann-Whitney Rank Sum Test when the data did not follow a normal distribution. When several experimental groups were analyzed, we used two-way analysis of variance (ANOVA). For locomotion experiments we used ANOVA with repeated measures, and when appropriate, a Tukey post hoc comparison test was used. For pharmacological MRI, the area under the curve of the signal time course was compared between VAChT<sup>D2-cre/flox/flox</sup> mice and control mice using a Student's <italic>t</italic> test.</p>
      </sec>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pbio.1001194.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.s001" xlink:type="simple">
        <label>Figure S1</label>
        <caption>
          <p>D2-Cre drives the expression of Cre in striatal cholinergic neurons. (a) Sections from different regions of the central nervous system were immunostained for CHT1 (Red) and YFP (Green) in D2-Cre;Rosa26-YFP mice. Arrows show localization of Cre expression (YFP) in cholinergic neurons (CHT1 staining). Arrowheads show cholinergic neurons that do not express Cre.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pbio.1001194.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.s002" xlink:type="simple">
        <label>Figure S2</label>
        <caption>
          <p>Representation of VAChT<sup>D2-Cre-flox/flox</sup> allele and identification by genotyping. (a) Cartoon representing the VAChT alleles before and after recombination. (b) PCR genotyping for VAChT<sup>flox/flox</sup> and VAChT<sup>D2-Cre-flox/flox</sup> mice. Lanes 1 and 2 WT PCR product, lane 3 flox/flox PCR product, and lane 4 heterozygous mice PCR product. (c) Lane 1 VAChT<sup>flox/flox</sup>, lane 2 VAChT<sup>D2-Cre-flox/flox</sup>, lane 3 VAChT<sup>D2-Cre-flox/flox</sup>, and lane 4 VAChT<sup>flox/flox</sup> genotyping.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pbio.1001194.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.s003" xlink:type="simple">
        <label>Figure S3</label>
        <caption>
          <p>Cholinergic parameters in the spinal cord of VAChT<sup>D2-Cre-flox/flox</sup> mice. (a, b, c) Quantification of mRNA expression for VAChT, ChAT, and CHT1, respectively, in the Spinal cord. (d, e, f) Quantification of protein levels in the Spinal cord for VAChT, ChAT, and CHT1, respectively. Synaptophysin immunoreactivity was used to correct for protein loading between experiments. (g) Representative Western blot of VAChT, synaptophysin, ChAT, CHT1, and actin ** <italic>p</italic>&lt;0.01 and *** <italic>p</italic>&lt;0.001.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pbio.1001194.s004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.s004" xlink:type="simple">
        <label>Figure S4</label>
        <caption>
          <p>Motor function is not altered in VAChT<sup>D2-Cre-flox/flox</sup> mice. (a) Grip-force analysis of VAChT<sup>flox/flox</sup> and VAChT<sup>D2-Cre-flox/flox</sup> mice. (b) Time spent hanging upside-down from a grid, to measure fatigue for VAChT<sup>flox/flox</sup> mice and VAChT<sup>D2-Cre-flox/flox</sup> mice (cut-off time 60 s). (c) Motor learning and acrobatic motor skills of VAChT<sup>D2-Cre-flox/flox</sup> mice determined using the rotarod (flox/flox, <italic>N</italic> = 14; D2-Cre-flox/flox, <italic>N</italic> = 17). (d) Object recognition memory in VAChT<sup>flox/flox</sup> and VAChT<sup>D2-Cre-flox/flox</sup> mice. * <italic>p</italic>&lt;0.05.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pbio.1001194.s005" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.s005" xlink:type="simple">
        <label>Figure S5</label>
        <caption>
          <p>Sensorimotor gating is not altered in VAChT<sup>D2-Cre-flox/flox</sup> mice. (a) Short-term habituation of acoustic startle responses to 30 acoustic startle stimuli of 115 db white noise delivered every 20 s. (b) Prepulse inhibition of acoustic startle responses with different prepulse intensities and prepulse-pulse intervals as indicated.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pbio.1001194.s006" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.s006" xlink:type="simple">
        <label>Figure S6</label>
        <caption>
          <p>Biochemical and behavioural parameters of heterozygous D2-Cre mice. (a) Horizontal activity as described in <xref ref-type="fig" rid="pbio-1001194-g004">Figure 4</xref>. (b) Total ambulance during 2 h. (c) Rearing during 2 h. (d) D1R mRNA, (e) D2R mRNA, an (f) mAChR-4 mRNA levels.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pbio.1001194.s007" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pbio.1001194.s007" xlink:type="simple">
        <label>Table S1</label>
        <caption>
          <p>Percentage of co-localization between cell with Cre-induced recombination and CHT1.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Jue Fan for animal husbandry and Miranda Bellyou for assistance with the MRI data collection; Dr. R. Jane Rylett and Dr. Arthur Brown (University of Western Ontario) for reagents; and Dr. Hymie Anisman (Carlton University, Ottawa, Canada), Dr. Stephen Ferguson, and Dr. John F. MacDonald (University of Western Ontario) for comments on earlier versions of this manuscript.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pbio.1001194-Aosaki1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Aosaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Miura</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>K</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>M</given-names></name></person-group>             <year>2010</year>             <article-title>Acetylcholine-dopamine balance hypothesis in the striatum: an update.</article-title>             <source>Geriatr Gerontol Int 10 Suppl</source>             <volume>1</volume>             <fpage>S148</fpage>             <lpage>S157</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Lovinger1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lovinger</surname><given-names>D. M</given-names></name></person-group>             <year>2010</year>             <article-title>Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum.</article-title>             <source>Neuropharmacology</source>             <volume>58</volume>             <fpage>951</fpage>             <lpage>961</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Surmeier1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Surmeier</surname><given-names>D. J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name><name name-style="western"><surname>Day</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W</given-names></name></person-group>             <year>2007</year>             <article-title>D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons.</article-title>             <source>Trends Neurosci</source>             <volume>30</volume>             <fpage>228</fpage>             <lpage>235</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Calabresi1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Calabresi</surname><given-names>P</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>B</given-names></name><name name-style="western"><surname>Parnetti</surname><given-names>L</given-names></name><name name-style="western"><surname>Di Filippo</surname><given-names>M</given-names></name></person-group>             <year>2006</year>             <article-title>A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.</article-title>             <source>Lancet Neurol</source>             <volume>5</volume>             <fpage>974</fpage>             <lpage>983</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Pisani1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pisani</surname><given-names>A</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>G</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name><name name-style="western"><surname>Surmeier</surname><given-names>D. J</given-names></name></person-group>             <year>2007</year>             <article-title>Re-emergence of striatal cholinergic interneurons in movement disorders.</article-title>             <source>Trends Neurosci</source>             <volume>30</volume>             <fpage>545</fpage>             <lpage>553</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Shen1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>W</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name><name name-style="western"><surname>Day</surname><given-names>M</given-names></name><name name-style="western"><surname>Ulrich</surname><given-names>S</given-names></name><name name-style="western"><surname>Tkatch</surname><given-names>T</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons.</article-title>             <source>Nat Neurosci</source>             <volume>10</volume>             <fpage>1458</fpage>             <lpage>1466</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-MacKenzie1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>MacKenzie</surname><given-names>R. G</given-names></name><name name-style="western"><surname>Stachowiak</surname><given-names>M. K</given-names></name><name name-style="western"><surname>Zigmond</surname><given-names>M. J</given-names></name></person-group>             <year>1989</year>             <article-title>Dopaminergic inhibition of striatal acetylcholine release after 6-hydroxydopamine.</article-title>             <source>Eur J Pharmacol</source>             <volume>168</volume>             <fpage>43</fpage>             <lpage>52</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-DeBoer1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>DeBoer</surname><given-names>P</given-names></name><name name-style="western"><surname>Heeringa</surname><given-names>M. J</given-names></name><name name-style="western"><surname>Abercrombie</surname><given-names>E. D</given-names></name></person-group>             <year>1996</year>             <article-title>Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D2 receptors.</article-title>             <source>Eur J Pharmacol</source>             <volume>317</volume>             <fpage>257</fpage>             <lpage>262</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-DeBoer2">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>DeBoer</surname><given-names>P</given-names></name><name name-style="western"><surname>Abercrombie</surname><given-names>E. D</given-names></name></person-group>             <year>1996</year>             <article-title>Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.</article-title>             <source>J Pharmacol Exp Ther</source>             <volume>277</volume>             <fpage>775</fpage>             <lpage>783</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-RodriguezOroz1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Oroz</surname><given-names>M. C</given-names></name><name name-style="western"><surname>Jahanshahi</surname><given-names>M</given-names></name><name name-style="western"><surname>Krack</surname><given-names>P</given-names></name><name name-style="western"><surname>Litvan</surname><given-names>I</given-names></name><name name-style="western"><surname>Macias</surname><given-names>R</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.</article-title>             <source>Lancet Neurol</source>             <volume>8</volume>             <fpage>1128</fpage>             <lpage>1139</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Torres1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>G. E</given-names></name><name name-style="western"><surname>Gainetdinov</surname><given-names>R. R</given-names></name><name name-style="western"><surname>Caron</surname><given-names>M. G</given-names></name></person-group>             <year>2003</year>             <article-title>Plasma membrane monoamine transporters: structure, regulation and function.</article-title>             <source>Nat Rev Neurosci</source>             <volume>4</volume>             <fpage>13</fpage>             <lpage>25</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Bennett1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>B. D</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C. J</given-names></name></person-group>             <year>1999</year>             <article-title>Spontaneous activity of neostriatal cholinergic interneurons in vitro.</article-title>             <source>J Neurosci</source>             <volume>19</volume>             <fpage>5586</fpage>             <lpage>5596</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Wilson1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>C. J</given-names></name></person-group>             <year>2005</year>             <article-title>The mechanism of intrinsic amplification of hyperpolarizations and spontaneous bursting in striatal cholinergic interneurons.</article-title>             <source>Neuron</source>             <volume>45</volume>             <fpage>575</fpage>             <lpage>585</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Parsons1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Parsons</surname><given-names>S. M</given-names></name></person-group>             <year>2000</year>             <article-title>Transport mechanisms in acetylcholine and monoamine storage.</article-title>             <source>FASEB J</source>             <volume>14</volume>             <fpage>2423</fpage>             <lpage>2434</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Ribeiro1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>F. M</given-names></name><name name-style="western"><surname>Black</surname><given-names>S. A</given-names></name><name name-style="western"><surname>Prado</surname><given-names>V. F</given-names></name><name name-style="western"><surname>Rylett</surname><given-names>R. J</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>S. S</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>The "ins" and "outs" of the high-affinity choline transporter CHT1.</article-title>             <source>J Neurochem</source>             <volume>97</volume>             <fpage>1</fpage>             <lpage>12</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-deCastro1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>de Castro</surname><given-names>B. M</given-names></name><name name-style="western"><surname>De Jaeger</surname><given-names>X</given-names></name><name name-style="western"><surname>Martins-Silva</surname><given-names>C</given-names></name><name name-style="western"><surname>Lima</surname><given-names>R. F</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>E</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>The vesicular acetylcholine transporter is required for neuromuscular development and function.</article-title>             <source>Mol Cell Biol</source>             <volume>29</volume>             <fpage>5238</fpage>             <lpage>5250</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Wess1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wess</surname><given-names>J</given-names></name><name name-style="western"><surname>Eglen</surname><given-names>R. M</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>D</given-names></name></person-group>             <year>2007</year>             <article-title>Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.</article-title>             <source>Nat Rev Drug Discov</source>             <volume>6</volume>             <fpage>721</fpage>             <lpage>733</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Zhou1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F. M</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C</given-names></name><name name-style="western"><surname>Dani</surname><given-names>J. A</given-names></name></person-group>             <year>2003</year>             <article-title>Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems.</article-title>             <source>Neuroscientist</source>             <volume>9</volume>             <fpage>23</fpage>             <lpage>36</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Zhou2">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F. M</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dani</surname><given-names>J. A</given-names></name></person-group>             <year>2001</year>             <article-title>Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum.</article-title>             <source>Nat Neurosci</source>             <volume>4</volume>             <fpage>1224</fpage>             <lpage>1229</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Drenan1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Drenan</surname><given-names>R. M</given-names></name><name name-style="western"><surname>Grady</surname><given-names>S. R</given-names></name><name name-style="western"><surname>Steele</surname><given-names>A. D</given-names></name><name name-style="western"><surname>McKinney</surname><given-names>S</given-names></name><name name-style="western"><surname>Patzlaff</surname><given-names>N. E</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors.</article-title>             <source>J Neurosci</source>             <volume>30</volume>             <fpage>9877</fpage>             <lpage>9889</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Drenan2">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Drenan</surname><given-names>R. M</given-names></name><name name-style="western"><surname>Grady</surname><given-names>S. R</given-names></name><name name-style="western"><surname>Whiteaker</surname><given-names>P</given-names></name><name name-style="western"><surname>Clure-Begley</surname><given-names>T</given-names></name><name name-style="western"><surname>McKinney</surname><given-names>S</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors.</article-title>             <source>Neuron</source>             <volume>60</volume>             <fpage>123</fpage>             <lpage>136</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Ren1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Habenula "cholinergic" neurons corelease glutamate and acetylcholine and activate postsynaptic neurons via distinct transmission modes.</article-title>             <source>Neuron</source>             <volume>69</volume>             <fpage>445</fpage>             <lpage>452</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Fremeau1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Fremeau</surname><given-names>R. T</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Burman</surname><given-names>J</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tran</surname><given-names>C. H</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>J</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>The identification of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate </article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>99</volume>             <fpage>14488</fpage>             <lpage>14493</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Herzog1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Herzog</surname><given-names>E</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>J</given-names></name><name name-style="western"><surname>Gras</surname><given-names>C</given-names></name><name name-style="western"><surname>Muzerelle</surname><given-names>A</given-names></name><name name-style="western"><surname>Ravassard</surname><given-names>P</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>Localization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain.</article-title>             <source>Neuroscience</source>             <volume>123</volume>             <fpage>983</fpage>             <lpage>1002</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Gras1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gras</surname><given-names>C</given-names></name><name name-style="western"><surname>Amilhon</surname><given-names>B</given-names></name><name name-style="western"><surname>Lepicard</surname><given-names>E. M</given-names></name><name name-style="western"><surname>Poirel</surname><given-names>O</given-names></name><name name-style="western"><surname>Vinatier</surname><given-names>J</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>The vesicular glutamate transporter VGLUT3 synergizes striatal acetylcholine tone.</article-title>             <source>Nat Neurosci</source>             <volume>11</volume>             <fpage>292</fpage>             <lpage>300</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Seal1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Seal</surname><given-names>R. P</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>R. H</given-names></name></person-group>             <year>2006</year>             <article-title>The diverse roles of vesicular glutamate transporter 3.</article-title>             <source>Handb Exp Pharmacol</source>             <volume>137-150</volume>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Higley1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Higley</surname><given-names>M. J</given-names></name><name name-style="western"><surname>Gittis</surname><given-names>A. H</given-names></name><name name-style="western"><surname>Oldenburg</surname><given-names>I. A</given-names></name><name name-style="western"><surname>Balthasar</surname><given-names>N</given-names></name><name name-style="western"><surname>Seal</surname><given-names>R. P</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Cholinergic interneurons mediate fast VGluT3-dependent glutamatergic transmission in the striatum.</article-title>             <source>PLoS ONE</source>             <volume>6</volume>             <fpage>e19155</fpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0019155" xlink:type="simple">10.1371/journal.pone.0019155</ext-link></comment>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Hikida1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hikida</surname><given-names>T</given-names></name><name name-style="western"><surname>Kitabatake</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pastan</surname><given-names>I</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>S</given-names></name></person-group>             <year>2003</year>             <article-title>Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>100</volume>             <fpage>6169</fpage>             <lpage>6173</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Hikida2">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hikida</surname><given-names>T</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>S</given-names></name><name name-style="western"><surname>Isobe</surname><given-names>T</given-names></name><name name-style="western"><surname>Kitabatake</surname><given-names>Y</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>D</given-names></name><etal/></person-group>             <year>2001</year>             <article-title>Increased sensitivity to cocaine by cholinergic cell ablation in nucleus accumbens.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>98</volume>             <fpage>13351</fpage>             <lpage>13354</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Kaneko1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kaneko</surname><given-names>S</given-names></name><name name-style="western"><surname>Hikida</surname><given-names>T</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>D</given-names></name><name name-style="western"><surname>Ichinose</surname><given-names>H</given-names></name><name name-style="western"><surname>Nagatsu</surname><given-names>T</given-names></name><etal/></person-group>             <year>2000</year>             <article-title>Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function.</article-title>             <source>Science</source>             <volume>289</volume>             <fpage>633</fpage>             <lpage>637</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Kitabatake1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kitabatake</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hikida</surname><given-names>T</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>D</given-names></name><name name-style="western"><surname>Pastan</surname><given-names>I</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>S</given-names></name></person-group>             <year>2003</year>             <article-title>Impairment of reward-related learning by cholinergic cell ablation in the striatum.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>100</volume>             <fpage>7965</fpage>             <lpage>7970</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-MartinsSilva1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Martins-Silva</surname><given-names>C</given-names></name><name name-style="western"><surname>De Jaeger</surname><given-names>X</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>M. S</given-names></name><name name-style="western"><surname>Lima</surname><given-names>R. D</given-names></name><name name-style="western"><surname>Santos</surname><given-names>M. S</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Novel strains of mice deficient for the vesicular acetylcholine transporter: insights on transcriptional regulation and control of locomotor behavior.</article-title>             <source>PLoS ONE</source>             <volume>6</volume>             <fpage>e17611</fpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0017611" xlink:type="simple">10.1371/journal.pone.0017611</ext-link></comment>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Gong1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>S</given-names></name><name name-style="western"><surname>Doughty</surname><given-names>M</given-names></name><name name-style="western"><surname>Harbaugh</surname><given-names>C. R</given-names></name><name name-style="western"><surname>Cummins</surname><given-names>A</given-names></name><name name-style="western"><surname>Hatten</surname><given-names>M. E</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs.</article-title>             <source>J Neurosci</source>             <volume>27</volume>             <fpage>9817</fpage>             <lpage>9823</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Campos1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>F</given-names></name><name name-style="western"><surname>Alfonso</surname><given-names>M</given-names></name><name name-style="western"><surname>Duran</surname><given-names>R</given-names></name></person-group>             <year>2010</year>             <article-title>In vivo modulation of alpha7 nicotinic receptors on striatal glutamate release induced by anatoxin-A.</article-title>             <source>Neurochem Int</source>             <volume>56</volume>             <fpage>850</fpage>             <lpage>855</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-deCastro2">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>de Castro</surname><given-names>B. M</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>G. S</given-names></name><name name-style="western"><surname>Magalhaes</surname><given-names>V</given-names></name><name name-style="western"><surname>Rossato</surname><given-names>J. I</given-names></name><name name-style="western"><surname>De Jaeger</surname><given-names>X</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Reduced expression of the vesicular acetylcholine transporter causes learning deficits in mice.</article-title>             <source>Genes Brain Behav</source>             <volume>8</volume>             <fpage>23</fpage>             <lpage>35</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Prado1">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Prado</surname><given-names>V. F</given-names></name><name name-style="western"><surname>Martins-Silva</surname><given-names>C</given-names></name><name name-style="western"><surname>de Castro</surname><given-names>B. M</given-names></name><name name-style="western"><surname>Lima</surname><given-names>R. F</given-names></name><name name-style="western"><surname>Barros</surname><given-names>D. M</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition.</article-title>             <source>Neuron</source>             <volume>51</volume>             <fpage>601</fpage>             <lpage>612</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Clarke1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>J. R</given-names></name><name name-style="western"><surname>Cammarota</surname><given-names>M</given-names></name><name name-style="western"><surname>Gruart</surname><given-names>A</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>I</given-names></name><name name-style="western"><surname>Delgado-Garcia</surname><given-names>J. M</given-names></name></person-group>             <year>2010</year>             <article-title>Plastic modifications induced by object recognition memory processing.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>107</volume>             <fpage>2652</fpage>             <lpage>2657</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Rossato1">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rossato</surname><given-names>J. I</given-names></name><name name-style="western"><surname>Bevilaqua</surname><given-names>L. R</given-names></name><name name-style="western"><surname>Myskiw</surname><given-names>J. C</given-names></name><name name-style="western"><surname>Medina</surname><given-names>J. H</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>I</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>On the role of hippocampal protein synthesis in the consolidation and reconsolidation of object recognition memory.</article-title>             <source>Learn Mem</source>             <volume>14</volume>             <fpage>36</fpage>             <lpage>46</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Winters1">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Winters</surname><given-names>B. D</given-names></name><name name-style="western"><surname>Bussey</surname><given-names>T. J</given-names></name></person-group>             <year>2005</year>             <article-title>Removal of cholinergic input to perirhinal cortex disrupts object recognition but not spatial working memory in the rat.</article-title>             <source>Eur J Neurosci</source>             <volume>21</volume>             <fpage>2263</fpage>             <lpage>2270</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Capettini1">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Capettini</surname><given-names>S. B</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>M. F</given-names></name><name name-style="western"><surname>Prado</surname><given-names>V. F</given-names></name><name name-style="western"><surname>Prado</surname><given-names>M. A</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>G. S</given-names></name></person-group>             <year>2011</year>             <article-title>Vesicular acetylcholine transporter knock-down mice show sexual dimorphism on memory.</article-title>             <source>Brain Res Bull</source>             <volume>85</volume>             <fpage>54</fpage>             <lpage>57</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Holt1">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Holt</surname><given-names>D. J</given-names></name><name name-style="western"><surname>Bachus</surname><given-names>S. E</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>T. M</given-names></name><name name-style="western"><surname>Wittie</surname><given-names>M</given-names></name><name name-style="western"><surname>Herman</surname><given-names>M. M</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Reduced density of cholinergic interneurons in the ventral striatum in schizophrenia: an in situ hybridization study.</article-title>             <source>Biol Psychiatry</source>             <volume>58</volume>             <fpage>408</fpage>             <lpage>416</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Holt2">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Holt</surname><given-names>D. J</given-names></name><name name-style="western"><surname>Herman</surname><given-names>M. M</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>T. M</given-names></name><name name-style="western"><surname>Kleinman</surname><given-names>J. E</given-names></name><name name-style="western"><surname>Sinton</surname><given-names>C. M</given-names></name><etal/></person-group>             <year>1999</year>             <article-title>Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia.</article-title>             <source>Neuroscience</source>             <volume>94</volume>             <fpage>21</fpage>             <lpage>31</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Laplante1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Laplante</surname><given-names>F</given-names></name><name name-style="western"><surname>Lappi</surname><given-names>D. A</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>R. M</given-names></name></person-group>             <year>2011</year>             <article-title>Cholinergic depletion in the nucleus accumbens: effects on amphetamine response and sensorimotor gating.</article-title>             <source>Prog Neuropsychopharmacol Biol Psychiatry</source>             <volume>35</volume>             <fpage>501</fpage>             <lpage>509</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Witten1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Witten</surname><given-names>I. B</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S. C</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>M</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>R</given-names></name><name name-style="western"><surname>Diester</surname><given-names>I</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Cholinergic interneurons control local circuit activity and cocaine conditioning.</article-title>             <source>Science</source>             <volume>330</volume>             <fpage>1677</fpage>             <lpage>1681</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Imperato1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Imperato</surname><given-names>A</given-names></name><name name-style="western"><surname>Obinu</surname><given-names>M. C</given-names></name><name name-style="western"><surname>Gessa</surname><given-names>G. L</given-names></name></person-group>             <year>1993</year>             <article-title>Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus.</article-title>             <source>Eur J Pharmacol</source>             <volume>238</volume>             <fpage>377</fpage>             <lpage>381</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Imperato2">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Imperato</surname><given-names>A</given-names></name><name name-style="western"><surname>Obinu</surname><given-names>M. C</given-names></name><name name-style="western"><surname>Demontis</surname><given-names>M. V</given-names></name><name name-style="western"><surname>Gessa</surname><given-names>G. L</given-names></name></person-group>             <year>1992</year>             <article-title>Cocaine releases limbic acetylcholine through endogenous dopamine action on D1 receptors.</article-title>             <source>Eur J Pharmacol</source>             <volume>229</volume>             <fpage>265</fpage>             <lpage>267</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Williams1">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>M. J</given-names></name><name name-style="western"><surname>Adinoff</surname><given-names>B</given-names></name></person-group>             <year>2008</year>             <article-title>The role of acetylcholine in cocaine addiction.</article-title>             <source>Neuropsychopharmacology</source>             <volume>33</volume>             <fpage>1779</fpage>             <lpage>1797</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Bohn1">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bohn</surname><given-names>L. M</given-names></name><name name-style="western"><surname>Gainetdinov</surname><given-names>R. R</given-names></name><name name-style="western"><surname>Sotnikova</surname><given-names>T. D</given-names></name><name name-style="western"><surname>Medvedev</surname><given-names>I. O</given-names></name><name name-style="western"><surname>Lefkowitz</surname><given-names>R. J</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice.</article-title>             <source>J Neurosci</source>             <volume>23</volume>             <fpage>10265</fpage>             <lpage>10273</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Robinson1">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>T. E</given-names></name><name name-style="western"><surname>Berridge</surname><given-names>K. C</given-names></name></person-group>             <year>2000</year>             <article-title>The psychology and neurobiology of addiction: an incentive-sensitization view.</article-title>             <source>Addiction 95 Suppl</source>             <volume>2</volume>             <fpage>S91</fpage>             <lpage>S117</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Kramer1">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kramer</surname><given-names>P. F</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>C. H</given-names></name><name name-style="western"><surname>Hazelwood</surname><given-names>L. A</given-names></name><name name-style="western"><surname>Dobi</surname><given-names>A</given-names></name><name name-style="western"><surname>Bock</surname><given-names>R</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Dopamine D2 receptor overexpression alters behavior and physiology in Drd2-EGFP mice.</article-title>             <source>J Neurosci</source>             <volume>31</volume>             <fpage>126</fpage>             <lpage>132</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Nguyen1">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>T. V</given-names></name><name name-style="western"><surname>Brownell</surname><given-names>A. L</given-names></name><name name-style="western"><surname>Iris Chen</surname><given-names>Y. C</given-names></name><name name-style="western"><surname>Livni</surname><given-names>E</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>J. T</given-names></name><etal/></person-group>             <year>2000</year>             <article-title>Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET.</article-title>             <source>Synapse</source>             <volume>36</volume>             <fpage>57</fpage>             <lpage>65</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Delfino1">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Delfino</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalisch</surname><given-names>R</given-names></name><name name-style="western"><surname>Czisch</surname><given-names>M</given-names></name><name name-style="western"><surname>Larramendy</surname><given-names>C</given-names></name><name name-style="western"><surname>Ricatti</surname><given-names>J</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging.</article-title>             <source>Neuropsychopharmacology</source>             <volume>32</volume>             <fpage>1911</fpage>             <lpage>1921</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Ogawa1">
        <label>53</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ogawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Tank</surname><given-names>D. W</given-names></name><name name-style="western"><surname>Menon</surname><given-names>R</given-names></name><name name-style="western"><surname>Ellermann</surname><given-names>J. M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. G</given-names></name><etal/></person-group>             <year>1992</year>             <article-title>Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>89</volume>             <fpage>5951</fpage>             <lpage>5955</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Miyakawa1">
        <label>54</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Miyakawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M</given-names></name><name name-style="western"><surname>Duttaroy</surname><given-names>A</given-names></name><name name-style="western"><surname>Wess</surname><given-names>J</given-names></name></person-group>             <year>2001</year>             <article-title>Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor.</article-title>             <source>J Neurosci</source>             <volume>21</volume>             <fpage>5239</fpage>             <lpage>5250</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Gerber1">
        <label>55</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gerber</surname><given-names>D. J</given-names></name><name name-style="western"><surname>Sotnikova</surname><given-names>T. D</given-names></name><name name-style="western"><surname>Gainetdinov</surname><given-names>R. R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S. Y</given-names></name><name name-style="western"><surname>Caron</surname><given-names>M. G</given-names></name><etal/></person-group>             <year>2001</year>             <article-title>Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>98</volume>             <fpage>15312</fpage>             <lpage>15317</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Gomeza1">
        <label>56</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Gomeza</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Kostenis</surname><given-names>E</given-names></name><name name-style="western"><surname>Felder</surname><given-names>C</given-names></name><name name-style="western"><surname>Bymaster</surname><given-names>F</given-names></name><etal/></person-group>             <year>1999</year>             <article-title>Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>96</volume>             <fpage>10483</fpage>             <lpage>10488</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Jeon1">
        <label>57</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Jeon</surname><given-names>J</given-names></name><name name-style="western"><surname>Dencker</surname><given-names>D</given-names></name><name name-style="western"><surname>Wortwein</surname><given-names>G</given-names></name><name name-style="western"><surname>Woldbye</surname><given-names>D. P</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors.</article-title>             <source>J Neurosci</source>             <volume>30</volume>             <fpage>2396</fpage>             <lpage>2405</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Smith1">
        <label>58</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H</given-names></name><name name-style="western"><surname>Rundquist</surname><given-names>S</given-names></name><name name-style="western"><surname>Maat-Schieman</surname><given-names>M. L</given-names></name><name name-style="western"><surname>Colgan</surname><given-names>L</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Cholinergic neuronal defect without cell loss in Huntington's disease.</article-title>             <source>Hum Mol Genet</source>             <volume>15</volume>             <fpage>3119</fpage>             <lpage>3131</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Allen1">
        <label>59</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>T. G</given-names></name><name name-style="western"><surname>Abogadie</surname><given-names>F. C</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D. A</given-names></name></person-group>             <year>2006</year>             <article-title>Simultaneous release of glutamate and acetylcholine from single magnocellular "cholinergic" basal forebrain neurons.</article-title>             <source>J Neurosci</source>             <volume>26</volume>             <fpage>1588</fpage>             <lpage>1595</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Hnasko1">
        <label>60</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hnasko</surname><given-names>T. S</given-names></name><name name-style="western"><surname>Chuhma</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Goh</surname><given-names>G. Y</given-names></name><name name-style="western"><surname>Sulzer</surname><given-names>D</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Vesicular glutamate transport promotes dopamine storage and glutamate corelease in vivo.</article-title>             <source>Neuron</source>             <volume>65</volume>             <fpage>643</fpage>             <lpage>656</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Stuber1">
        <label>61</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Stuber</surname><given-names>G. D</given-names></name><name name-style="western"><surname>Hnasko</surname><given-names>T. S</given-names></name><name name-style="western"><surname>Britt</surname><given-names>J. P</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>R. H</given-names></name><name name-style="western"><surname>Bonci</surname><given-names>A</given-names></name></person-group>             <year>2010</year>             <article-title>Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate.</article-title>             <source>J Neurosci</source>             <volume>30</volume>             <fpage>8229</fpage>             <lpage>8233</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-ElMestikawy1">
        <label>62</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>El Mestikawy</surname><given-names>S</given-names></name><name name-style="western"><surname>Wallen-Mackenzie</surname><given-names>A</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>G. M</given-names></name><name name-style="western"><surname>Descarries</surname><given-names>L</given-names></name><name name-style="western"><surname>Trudeau</surname><given-names>L. E</given-names></name></person-group>             <year>2011</year>             <article-title>From glutamate co-release to vesicular synergy: vesicular glutamate transporters.</article-title>             <source>Nat Rev Neurosci</source>             <volume>12</volume>             <fpage>204</fpage>             <lpage>216</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-LimaRde1">
        <label>63</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lima Rde</surname><given-names>F</given-names></name><name name-style="western"><surname>Prado</surname><given-names>V. F</given-names></name><name name-style="western"><surname>Prado</surname><given-names>M. A</given-names></name><name name-style="western"><surname>Kushmerick</surname><given-names>C</given-names></name></person-group>             <year>2010</year>             <article-title>Quantal release of acetylcholine in mice with reduced levels of the vesicular acetylcholine transporter.</article-title>             <source>J Neurochem</source>             <volume>113</volume>             <fpage>943</fpage>             <lpage>951</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Spalding1">
        <label>64</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Spalding</surname><given-names>T. A</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>E. S</given-names></name></person-group>             <year>2006</year>             <article-title>Constitutive activity of muscarinic acetylcholine receptors.</article-title>             <source>J Recept Signal Transduct Res</source>             <volume>26</volume>             <fpage>61</fpage>             <lpage>85</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Galandrin1">
        <label>65</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Galandrin</surname><given-names>S</given-names></name><name name-style="western"><surname>Oligny-Longpre</surname><given-names>G</given-names></name><name name-style="western"><surname>Bouvier</surname><given-names>M</given-names></name></person-group>             <year>2007</year>             <article-title>The evasive nature of drug efficacy: implications for drug discovery.</article-title>             <source>Trends Pharmacol Sci</source>             <volume>28</volume>             <fpage>423</fpage>             <lpage>430</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Giros1">
        <label>66</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Giros</surname><given-names>B</given-names></name><name name-style="western"><surname>Jaber</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S. R</given-names></name><name name-style="western"><surname>Wightman</surname><given-names>R. M</given-names></name><name name-style="western"><surname>Caron</surname><given-names>M. G</given-names></name></person-group>             <year>1996</year>             <article-title>Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.</article-title>             <source>Nature</source>             <volume>379</volume>             <fpage>606</fpage>             <lpage>612</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Bonsi1">
        <label>67</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bonsi</surname><given-names>P</given-names></name><name name-style="western"><surname>Martella</surname><given-names>G</given-names></name><name name-style="western"><surname>Cuomo</surname><given-names>D</given-names></name><name name-style="western"><surname>Platania</surname><given-names>P</given-names></name><name name-style="western"><surname>Sciamanna</surname><given-names>G</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Loss of muscarinic autoreceptor function impairs long-term depression but not long-term potentiation in the striatum.</article-title>             <source>J Neurosci</source>             <volume>28</volume>             <fpage>6258</fpage>             <lpage>6263</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Guo1">
        <label>68</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M. L</given-names></name><name name-style="western"><surname>Fibuch</surname><given-names>E. E</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X. Y</given-names></name><name name-style="western"><surname>Choe</surname><given-names>E. S</given-names></name><name name-style="western"><surname>Buch</surname><given-names>S</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>CaMKIIalpha interacts with M4 muscarinic receptors to control receptor and psychomotor function.</article-title>             <source>EMBO J</source>             <volume>29</volume>             <fpage>2070</fpage>             <lpage>2081</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Ferreira1">
        <label>69</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>L. T</given-names></name><name name-style="western"><surname>Santos</surname><given-names>M. S</given-names></name><name name-style="western"><surname>Kolmakova</surname><given-names>N. G</given-names></name><name name-style="western"><surname>Koenen</surname><given-names>J</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>J</given-names><suffix>Jr</suffix></name><etal/></person-group>             <year>2005</year>             <article-title>Structural requirements for steady-state localization of the vesicular acetylcholine transporter.</article-title>             <source>J Neurochem</source>             <volume>94</volume>             <fpage>957</fpage>             <lpage>969</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Lara1">
        <label>70</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lara</surname><given-names>A</given-names></name><name name-style="western"><surname>Damasceno</surname><given-names>D. D</given-names></name><name name-style="western"><surname>Pires</surname><given-names>R</given-names></name><name name-style="western"><surname>Gros</surname><given-names>R</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>E. R</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure.</article-title>             <source>Mol Cell Biol</source>             <volume>30</volume>             <fpage>1746</fpage>             <lpage>1756</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Ribeiro2">
        <label>71</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>F. M</given-names></name><name name-style="western"><surname>Alves-Silva</surname><given-names>J</given-names></name><name name-style="western"><surname>Volknandt</surname><given-names>W</given-names></name><name name-style="western"><surname>Martins-Silva</surname><given-names>C</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>H</given-names></name><etal/></person-group>             <year>2003</year>             <article-title>The hemicholinium-3 sensitive high affinity choline transporter is internalized by clathrin-mediated endocytosis and is present in endosomes and synaptic vesicles.</article-title>             <source>J Neurochem</source>             <volume>87</volume>             <fpage>136</fpage>             <lpage>146</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Ribeiro3">
        <label>72</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>F. M</given-names></name><name name-style="western"><surname>Black</surname><given-names>S. A</given-names></name><name name-style="western"><surname>Cregan</surname><given-names>S. P</given-names></name><name name-style="western"><surname>Prado</surname><given-names>V. F</given-names></name><name name-style="western"><surname>Prado</surname><given-names>M. A</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Constitutive high-affinity choline transporter endocytosis is determined by a carboxyl-terminal tail dileucine motif.</article-title>             <source>J Neurochem</source>             <volume>94</volume>             <fpage>86</fpage>             <lpage>96</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Barbosa1">
        <label>73</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Barbosa</surname><given-names>J</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Clarizia</surname><given-names>A. D</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>M. V</given-names></name><name name-style="western"><surname>RomanoSilva</surname><given-names>M. A</given-names></name><name name-style="western"><surname>Prado</surname><given-names>V. F</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>Effect of protein kinase C activation on the release of [H-3]Acetylcholine in the presence of vesamicol.</article-title>             <source>Journal of Neurochemistry</source>             <volume>69</volume>             <fpage>2608</fpage>             <lpage>2611</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Dunkley1">
        <label>74</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dunkley</surname><given-names>P. R</given-names></name><name name-style="western"><surname>Jarvie</surname><given-names>P. E</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>P. J</given-names></name></person-group>             <year>2008</year>             <article-title>A rapid Percoll gradient procedure for preparation of synaptosomes.</article-title>             <source>Nat Protoc</source>             <volume>3</volume>             <fpage>1718</fpage>             <lpage>1728</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Dunkley2">
        <label>75</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dunkley</surname><given-names>P. R</given-names></name><name name-style="western"><surname>Jarvie</surname><given-names>P. E</given-names></name><name name-style="western"><surname>Heath</surname><given-names>J. W</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>G. J</given-names></name><name name-style="western"><surname>Rostas</surname><given-names>J. A</given-names></name></person-group>             <year>1986</year>             <article-title>A rapid method for isolation of synaptosomes on Percoll gradients.</article-title>             <source>Brain Res</source>             <volume>372</volume>             <fpage>115</fpage>             <lpage>129</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Prado2">
        <label>76</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Prado</surname><given-names>M. A. M</given-names></name><name name-style="western"><surname>Guatimosim</surname><given-names>C</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>M. V</given-names></name><name name-style="western"><surname>Diniz</surname><given-names>C. R</given-names></name><name name-style="western"><surname>Cordeiro</surname><given-names>M. N</given-names></name><etal/></person-group>             <year>1996</year>             <article-title>A novel tool for the investigation of glutamate release from rat cerebrocortical synaptosomes: The toxin Tx3-3 from the venom of the spider Phoneutria nigriventer.</article-title>             <source>Biochemical Journal</source>             <volume>314</volume>             <fpage>145</fpage>             <lpage>150</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Nicholls1">
        <label>77</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nicholls</surname><given-names>D. G</given-names></name><name name-style="western"><surname>Sihra</surname><given-names>T. S</given-names></name><name name-style="western"><surname>Sanchez-Prieto</surname><given-names>J</given-names></name></person-group>             <year>1987</year>             <article-title>Calcium-dependent and -independent release of glutamate from synaptosomes monitored by continuous fluorometry.</article-title>             <source>J Neurochem</source>             <volume>49</volume>             <fpage>50</fpage>             <lpage>57</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Guatimosim1">
        <label>78</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Guatimosim</surname><given-names>C</given-names></name><name name-style="western"><surname>RomanoSilva</surname><given-names>M. A</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>J. S</given-names></name><name name-style="western"><surname>Beirao</surname><given-names>P. S. L</given-names></name><name name-style="western"><surname>Kalapothakis</surname><given-names>E</given-names></name><etal/></person-group>             <year>1997</year>             <article-title>A toxin from the spider Phoneutria nigriventer that blocks calcium channels coupled to exocytosis.</article-title>             <source>British Journal of Pharmacology</source>             <volume>122</volume>             <fpage>591</fpage>             <lpage>597</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Schmid1">
        <label>79</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Schmid</surname><given-names>S</given-names></name><name name-style="western"><surname>Azzopardi</surname><given-names>E</given-names></name><name name-style="western"><surname>De Jaeger</surname><given-names>X</given-names></name><name name-style="western"><surname>Prado</surname><given-names>M. A</given-names></name><name name-style="western"><surname>Prado</surname><given-names>V. F</given-names></name></person-group>             <year>2011</year>             <article-title>VAChT knock-down mice show normal prepulse inhibition but disrupted long-term habituation.</article-title>             <source>Genes Brain Behav</source>             <volume>10</volume>             <fpage>457</fpage>             <lpage>464</lpage>          </element-citation>
      </ref>
      <ref id="pbio.1001194-Brown1">
        <label>80</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>R. M</given-names></name><name name-style="western"><surname>Short</surname><given-names>J. L</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>A. J</given-names></name></person-group>             <year>2010</year>             <article-title>Identification of brain nuclei implicated in cocaine-primed reinstatement of conditioned place preference: a behaviour dissociable from sensitization.</article-title>             <source>PLoS ONE</source>             <volume>5</volume>             <fpage>e15889</fpage>             <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0015889" xlink:type="simple">10.1371/journal.pone.0015889</ext-link></comment>          </element-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>BOLD</term>
          <def>
            <p>blood oxygenation level-dependent</p>
          </def>
        </def-item>
        <def-item>
          <term>ChAT</term>
          <def>
            <p>choline acetyltransferase</p>
          </def>
        </def-item>
        <def-item>
          <term>CHT1</term>
          <def>
            <p>high-affintiy choline transporter</p>
          </def>
        </def-item>
        <def-item>
          <term>CPP</term>
          <def>
            <p>conditioned place preference</p>
          </def>
        </def-item>
        <def-item>
          <term><italic>ph</italic>MRI</term>
          <def>
            <p>pharmacological MRI</p>
          </def>
        </def-item>
        <def-item>
          <term>PPI</term>
          <def>
            <p>pre-pulse inhibition</p>
          </def>
        </def-item>
        <def-item>
          <term>VAChT</term>
          <def>
            <p>vesicular acetylcholine transporter</p>
          </def>
        </def-item>
        <def-item>
          <term>VGLUT3</term>
          <def>
            <p>vesicular glutamate transporter 3</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    
  </back>
</article>